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CHAPTER 1 
INTRODUCTION AND OUTLINE OF INVESTIGATIONS 
Introduction 
The pathogenesis of peptic ulcer is believed to be multifactorial but its 
aetiology has not been fully established.Several of the factors contributing 
to the development of peptic ulcers have been studied (1). A key role has 
always been attributed to gastric acid. In 1910 Schwartz postulated that 
without the presence of gastric acid no peptic ulcer can develop and his 
dictum: "no acid no ulcer" has withstood the ravages of time (2). 
Gastric acid is produced by the parietal cells in corpus and fundus of the 
stomach. Three substances in the body are known to be capable of stimulating 
the parietal cells to produce hydrochloric acid. These are acetylcholine, 
gastrin and histamine. The parietal cells probably have three different re-
ceptors for each of these 3 substances (3). The 3 receptors interact 
with each other:a threshold stimulation by one greatly enhances the responses 
to the 2 other stimuli, and blockade of one of these receptors concomitantly 
blocks the effects of stimulation on the others (4). Acetylcholine and gastrin 
are known to play important physiological roles. Acetylcholine is liberated 
from the parietal cell after vagal stimulation. The hormone gastrin is secre-
ted by gastrin producing cells in the antral and duodenal mucosa in response 
to several stimuli. Gastrin reaches the parietal cells via the bloodstream. 
Until recently the physiologic role of histamine in gastric acid secretion has 
been disputed. 
Histamine is formed by decarboxylation of histamine (fig 1). Histamine is 
present in large amounts in most body tissues including the gastric mucosa 
(5). Its main effects have been reported in a number of papers by Dale and 
Laidlaw: histamine causes contraction of smooth muscle in bronchi, ileum 
and arteries.it increases the heart rate and inhibits uterine contractions 
(6). The gastric acid stimulatory effect of histamine was later discovered 
by Popielsky (7). The first substances which were able to antagonize histamine 
were described by Bovet and Staub (8). Surprisingly, these classical antihis-
tamines did not inhibit all effects of histamine. They had, for instance, no 
effect on the gastric acid stimulatory capacity of histamine. In 1966, Ash and 
Schild defined the effects of histamine antagonized by the conventional anti-
histamines as mediated through H.-receptors, and those who were not by H--
receptors (9). 
The classical antihistamines shared the side-chain with histamine while the 
imidazole ring was modified (fig 1). Black and co-workers succeeded in syn-
thesizing specific H?-receptor blocking compounds by modifying the side-chain 
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of the histamine molecule leaving the imidazole ring intact (10) (fig 1). 
HC = C — C —C — N H , 
ΗΝ N COOH 
V 
h 
histidine 
[decarboxylation 
HC = C- -C — N H , 
H 
-ANTAGONIST 
\ 
C—C—C — N C 
Ή н2 н г н - с н 3 
ΗΝ N 
Η 
histamine H 2 -ANTAGONISTS 
N 
chlorpheniramine 
C ^ C — C — S — C — Ο ­
Ι | h j H 2 H 2 
ΗΝ N 
Η 
m e t i a m i d e 
N — С — Ν -
H H H 
S 
C H , 
" C = C — C — S — C — C - - N — C — N - - C H 
ΗΝ N 
С 
H 
Cimetidine 
H || H 
N-C=N; 
Fig 1 The formation of histamine by decarboxylation of histidine and some 
examples of l·^- and H.-receptor blocking agents. The shaded area in 
the metiamide formula represents the thiourea moiety and in the 
Cimetidine formula the cyanoguanidine group. 
In a recent article 2 key members of this team describe the long and laborious 
road they had to go before their goal was achieved (11). From 1964 to 1970 
some 700 compounds had been synthesized and tested before burimamide, the 
first competitive antagonist of histamine on H--receptors,was discovered. 
The effect of burimamide was weak and it was not active orally (10). Metiamide 
the second Hj-receptor antagonist was a potent inhibitor of gastric acid se­
cretion and was well absorbed from the gut (12). It caused, however, agranulo­
cytosis in a number of cases and therefore it was withdrawn (13). This com­
plication is attributed to the thiourea group of the side-chain. In the third 
Hp-receptor antagonist this group has been substituted by a cyanogua-
nidine group (14) (fig 1). This new compound, Cimetidine, proved to be a 
potent inhibitor of gastric acid secretion, provoked by all known stimuli 
(15). 
All therapies for peptic ulcer disease have been directed towards a reduc­
tion of gastric acid. Surgical treatment reduces gastric acid by cutting the 
vagal nerves (vagotomy) or removing the gastrin producing cells (antrectomy). 
In medical treatment often antacids and/or anticholinergics are prescribed. 
Antacids reduce intragastric acidity by buffering intraluminal gastric acid. 
To achieve ulcer healing, however, frequent and high doses are required (16). 
Anticholinergics inhibit vagally stimulated gastric acid secretion. In effec­
tive doses, however, they produce side effects and a favourable effect of 
anticholinergics on ulcer healing has not been proven (17). 
Therefore this new drug, Cimetidine, capable of inhibiting gastric acid 
secretion without these disadvantages, was very promising. It offered the 
prospect of a more effective medical treatment for peptic ulcer and thus 
possibly a decrease in the necessity for surgical procedures. 
Outline of investigations 
The aim of this study was to investigate the usefulness of treatment with 
Cimetidine in peptic ulcer disease. 
Firstly, the effect of Cimetidine on gastric acid secretion was examined 
(chapter 2). Thereafter the role of Cimetidine in the treatment of various 
acid peptic diseases was established: in duodenal and gastric ulcer (chapter 
2), and in recurrent ulcer after partial gastrectomy (chapter 3). In reflux 
oesophagitis gastric acid is also believed to play an important role. Results 
of treatment of this condition with Cimetidine are given in chapter 4. In the 
Zollinger-Ellison syndrome hypersecretion of gastric acid with all its conse­
quences is caused by hypergastrinaemia originating from a gastrin producing 
tumor. Short and long term treatment of these patients with Cimetidine was 
studied (chapter 5). The effect of long term treatment with Cimetidine on 
gastric acid secretion, serum gastrin, the blood Cimetidine levels and the 
acid inhibitory effect of Cimetidine is presented in chapter 6. In chapter 7 
the intra- and interindividual variability of blood concentration of Cimeti­
dine after an oral gift was studied. Retrospectively these concentrations were 
related to the clinical effect of treatment with Cimetidine in patients with 
peptic ulcer. 
As Hp-receptors are also present on Τ lymphocytes (18), possible immunolo­
gical effects of treatment with Cimetidine were studied in man (chapter 8) 
10 
and in a transplantation model of inbred mice (chapter 9). 
Finally a review of the literature on the clinical use of Cimetidine is 
presented in chapter 10. 
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CHAPTER 2 
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Abstract 
A reduction in the basal as well as the pentagastrin stimulated gastric 
acid secretion was observed after administration of 200 mg Cimetidine to I*» 
patients with a duodenal and 8 with a gastric ulcer. In a double blind study, 
the effect of Cimetidine was compared to that of a placebo. In a group of 23 
duodenal ulcer patients, 10 out of 12 patients treated with Cimetidine showed 
healed ulcers after k weeks treatment, compared to 2 out of 11 patients trea-
ted with a placebo (p<0.01). Duodenal ulcer patients treated with Cimetidine 
also exhibited a significant alleviation of ulcer symptoms. 
Nine out of 13 gastric ulcer patients treated with Cimetidine showed hea-
ling of the ulcer after 't weeks and h out of 11 patients treated with a pla-
cebo (not significant). In gastric ulcer patients Cimetidine as well as pla-
cebo achieved significant symptom relief. 
Concerning side effects, some patients in the Cimetidine group and to a 
lesser extent in the placebo group, exhibited a slight transient increase of 
the serum creatinine and SGPT levels. 
Introduction 
It has been shown that Cimetidine effectively inhibits nocturnal (1,2) and 
meal stimulated (3-6) gastric acid secretion. Presently, Cimetidine is exten-
sively tested for the treatment of peptic ulcer disease (7-11). 
This paper describes the reduction of gastric acid secretion using Cimeti-
dine, and the results of a double blind investigation of the effect of Cime-
tidine in the treatment of peptic ulcers. 
Patients and methods 
Twenty-three patients with a duodenal and 24 with a gastric ulcer were 
studied. The ulcer was confirmed by endoscopy within one week before they 
entered the trial. Patients were treated as outpatients and were randomly, 
in double blind fashion, allocated to Cimetidine 3 times daily, 200 mg 
after meals and 400 mg at bedtime, or matching placebo. All other ulcer me-
dication was discarded and no diet was prescribed. Each patient was given a 
diary card to record ulcer symptoms day and night. Patients were seen at 
weekly intervals, at each visit they were asked for symptoms, side effects 
and diary cards were checked. Before the trial, after 2 weeks, and at the 
end of it, routine haematological and biochemical blood studies and urine 
analysis were performed (haemoglobin, haematocrit, red blood cell count, total 
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white blood cell count, differential and platelet count, creatinine, urea, 
uric acid, bilirubin, alkaline phosphatase, SGOT and SGPT). After 4 weeks 
treatment gastroscopy was repeated by an endoscopist who was not aware of 
the type of treatment of the patient. Patients were only considered healed 
when endoscopy after treatment revealed no ulcer. 
Before treatment gastric acid secretion was determined in all patients 
with a duodenal ulcer and in 18 of the 24 gastric ulcer patients. After an 
overnight fast, a gastric tube was positioned according to the method des-
cribed by Hector (12). Basal acid output was measured during one hour and 
subsequently maximal acid output during one hour after injection of penta-
gastrin (6 pg/kg i.m.). Hydrogen ion concentration (meq H /1) was determined 
by titration with O.IN NaOH up to pH 7.0. 
Gastric acid secretion after Cimetidine was measured in 14 patients with 
a duodenal and in 8 patients with a gastric ulcer. In these patients gastric 
analysis was performed as described above one hour after oral intake of 200 
mg Cimetidine, with this difference that basal acid output was measured 
during 30 minutes. 
For statistical analysis, Wilcoxon's rank sum test and X test were used. 
Results 
The effe^t_o.f £Іте^ісНде_ог^ £astri£ a^cj_d_sec£etiдп 
The basal as well as the pentagastrin stimulated gastric acid secretion 
decreased significantly in all patients after administration of Cimetidine. 
In duodenal ulcer patients the basal acid output decreased by an average of 
92% (range 79-100%; p<0.01) and the maximal acid output by an average of 58% 
(range 18-83%; p<0.01). In gastric ulcer patients basal acid output diminished 
by an average of 97% (range 92-100%; p<0.05) and maximal acid output by an 
average of 50% (range 27-94%; p<0.01) (fig 1). 
The effect_of c^meti^ine_0£ £ ΐ « τ Jiea^ ljjig .^n^ on_u2cer_sym£toms 
Patient characteristics are given in table 1. There were no significant 
differences between the Cimetidine and the placebo groups regarding age, sex, 
duration of disease or gastric acid secretion. 
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DUODENAL ULCER GASTRIC ULCER 
mEq H + 
5 0 τ 
4 0 -
3 0 -
2 0 -
1 0 -
0 - 1 
Fig 1 
P < 0 0 1 
2 0 0 m g 
Cimetidine 
BAO 
p < 0 0 5 
200 mg 
Cimetidine 
MAO 
2 0 0 m g 
Cimetidine 
BAO 
2 0 0 m g 
Cimetidine 
MAO 
Basal (BAO) and maximal acid output (MAO) without medication and one 
hour after 200 mg Cimetidine orally in 1Ί duodenal and 8 gastric 
ulcer patients. BAO was measured for 30 minutes and MAO was measured 
for one hour. 
Ouodena1 _u Jeeг 
After 4 weeks treatment the ulcer had healed in 10 out of 12 patients 
treated with Cimetidine and in 2 out of 11 patients on placebo (p<0.01) 
(table 2). Ulcer symptoms were expressed as the number of days with pain 
per week. The symptoms in the week prior to the trial were comparable in 
both groups. During treatment ulcer symptoms decreased in both groups of 
patients. However, only in Cimetidine treated patients symptomatic improve­
ment during treatment was statistically significant in all treatment weeks 
when compared to the week before the trial (fig 2). 
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Fig 2 The effect of Cimetidine and placebo on ulcer symptoms expressed as the 
number of days with ulcer symptoms weekly in the week prior to treat­
ment (week -1) and during the k weeks of treatment (week 1-Ό, in duo­
denal (top panel) and gastric ulcer patients (bottom panel). Arrow in­
dicates start of treatment. p-Values indicate statistical differences 
between treatment week compared with the one before the trial(week -1). 
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Table 1 CHARACTERISTICS OF PATIENTS 
С i met id¡ne Placebo 
Duodena1_и1eer 
age (yr) 
male/female 
duration of disease (yr) 
basal acid output (meq/hr) 
maximal acid output (meq/hr) 
50 + if 
12 / 0 
12 + 2 
8.3+1.6 
29.6+3.0 
k3 + 6 
10 / 1 
7 ± 2 
^.2+0.9 
2Ц.3+2.0 
Gastric ulcer 
age (yr) 
mal e/ferna 1 e 
duration of disease (yr) 
basal acid output (meq/hr) 
maximal acid output (meq/hr) 
hS ± 3 
11 / 2 
3 ± 1 
i.it+o.a* 
10.7+1.9* 
52 + 3 
5 / 6 
9 + 3 
1.8+0.3** 
13.0+1.9** 
Data are presented as the mean + SEM 
* nine out of 13 patients studied 
** nine out of 11 patients studied 
Table 2 THE EFFECT OF CIMETIDINE AND PLACEBO ON ULCER HEALING 
healed unhea1 ed 
Duodenal ulcer 
Gastric ulcer 
cimet i d i ne 
placebo 
cimet i d i ne 
placebo 
10 
2 
9 
it 
p<0.01 
ns = the difference is statistically not significant 
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G a st г-к £ΐ eer 
After 4 weeks treatment the ulcers in 9 out of 13 Cimetidine treated pa­
tients had healed compared with 4 out of 11 patients on placebo (ns) 
(table 2). In both Cimetidine and placebo treated patients ulcer symptoms 
diminished significantly during treatment in all 4 weeks compared to the 
week prior to the trial (fig 2). 
^i^e_e fleets 
One patient complained of headache and another of skin rash. Both had been 
as it turned out, on placebo. In 5 patients on Cimetidine, who had shown 
normal serum creatinine concentrations (<100ymol/l) before treatment, an 
increase to above-normal values was observed (102-115 ymol/1). These con­
centrations returned in all patients to initial values during further treat­
ment with Cimetidine, after the trial. 
In 5 patients, who had increased serum creatinine concentrations (102-159 
pmol/l) prior to Cimetidine treatment, a further increase was observed 
(114-182 ymol/l), but also this increase was temporary as was shown during 
further treatment with Cimetidine. In 2 patients receiving placebo a tem­
porary increase in serum creatinine concentration to above-normal levels was 
observed (104 and 125 ymol/1). 
During Cimetidine treatment in 6 patients an increase in SGPT to above nor­
mal levels (16-45 u/1) was observed. In all 6 cases values were normal before 
treatment. The transaminase concentration normalized during further treatment 
with Cimetidine. Two patients in the placebo group also had a temporary in­
crease of SGPT levels (to 18 u/1). 
The other laboratory tests studied continued to be normal. 
Discussion 
This study confirms that Cimetidine greatly reduces gastric acid secretion. 
In duodenal, as well as gastric ulcer patients, basal and pentagastrin stimu­
lated gastric acid secretion was greatly inhibited (13,14). Moreover, Cimeti­
dine proved to have a favourable effect on the healing of duodenal ulcer and 
had a clearly favourable effect on the ulcer symptoms of these patients. Our 
results are in agreement with those of other observers (7-11). 
In gastric ulcer patients however, the effect of Cimetidine treatment was 
less clear. Neither in the healing of ulcers, nor in the alleviation of ulcer 
symptoms, Cimetidine proved to be superior over a placebo. A number of studies 
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report findings corresponding with our observation (15,16). Some investiga­
tors however, reported a significantly better effect of Cimetidine compared 
to a placebo in the healing of gastric ulcers, but also in these studies no 
favourable effect of Cimetidine treatment on ulcer symptoms could be establi­
shed (17,18). 
No important side effects were noted. Gynaecomastia, as reported by others 
(19,20), did not occur in any of our patients. In several patients, a slight 
transient rise of serum creatinine concentration and SGPT levels was obser­
ved. Comparing data of other investigators it would appear, that temporary 
serum creatinine increases occur in 11% of patients treated with Cimetidine 
and in 6.6% of those receiving a placebo (21). 
In conclusion: Cimetidine was a potent inhibitor of gastric acid secre­
tion. Furthermore, in duodenal ulcer patients Cimetidine proved to be effec­
tive in healing ulcers and relieving ulcer symptoms. In gastric ulcer patients 
however, treatment with Cimetidine was not superior over a placebo. 
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Abstract 
In order to assess the efficacy of Cimetidine in patients with endoscopi-
cally proved anastomotic ulcer after partial gastrectomy, 21 such patients 
entered a double blind prospective clinical trial. At endoscopy after ¿) weeks 
of treatment, 8 of 12 patients treated with 1 g Cimetidine daily compared 
wi th one of 9 patients who received a placebo had healed ulcers (p<0.05). 
Evaluation of symptom relief supported the efficacy of Cimetidine compared 
with placebo. Healing rate after one month of treatment with Cimetidine was 
671 and increased to 86% after 2 months. During one year of maintenance therapy 
with 800 mg Cimetidine daily, 3 of 19 patients relapsed. No serious side 
effects were observed. The results of this study demonstrate a beneficial 
effect of Cimetidine on healing and symptoms of anastomotic ulcers. 
Introduction 
Partial gastrectomy is a widely used surgical treatment in patients with 
peptic ulcer disease. A number of these patients, however, suffer anastomotic 
ulceration. Recurrence rates differ, from 3.7% after subtotal gastrectomy 
alone to 0.7% if also vagotomy was performed (1). 
Anastomotic ulcers differ from duodenal ulcer in that they occur usually 
with lower acid output. Furthermore, medical treatment of anastomotic ulcers 
is not as successful as that of duodenal ulcers, nor is surgical treatment, 
whereas the latter presents with a high mortality rate (2,3). It has been 
shown previously that Hp-receptor antagonists are beneficial in the treat-
ment of duodenal ulcer (4,5,6). The present study was undertaken to assess 
the efficacy of the hL-receptor antagonist Cimetidine in the treatment of 
patients with anastomotic ulcer after partial gastrectomy. 
Patients and methods 
Twenty-one patients with anastomotic ulcer after partial gastrectomy with 
Billroth I (BI) or Billroth II (BII) anastomosis were studied. The ulcer was 
confirmed by endoscopy within 3 days of the patients' entering the trial. 
Only patients with ulcers measuring 5 mm in diameter (the diameter of an open 
biopsy forceps) or more were admitted to the trial. 
Patients were treated as outpatients and were randomly, in double-blind 
fashion, allocated to Cimetidine 3 times daily, 200 mg after meals and 
400 mg at bedtime, or matching placebo. In addition, they were free to use 
antacid tablets, containing 578 mg calcium carbonate and 75.5 mg magnesium 
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carbonate per tablet, in case of ulcer dyspepsia. All other ulcer medication 
was discontinued. Patients who used drugs with known or suggested ulcerogenic 
properties were excluded from the study. A standard gastric analysis using 
pentagastrin, 6 pg/kg, was performed before the study in all but 4 patients. 
Each patient was given a diary card to record day and night ulcer symptoms and 
antacid consumption. Patients were seen at weekly intervals, and at each visit 
they were asked for symptoms and side effects and diary cards were checked. 
Before, after 2 weeks, and at the end of the trial, routine hematologic and 
biochemical blood studies and urine analysis were performed (hemoglobin, 
hematocrit, red blood cell count, total white blood cell count, differential 
and platelet count, creatinine, urea, uric acid, bilirubin, alkaline phospha­
tase, SGOT and SGPT). After 4 weeks of treatment, endoscopy was repeated, and 
ulcers were recorded as either healed or unhealed. For statistical analysis, 
Wilcoxon's rank sum test and X test were used. 
Results 
Patient characteristics are given in table 1. 
Table 1 PATIENT CHARACTERISTICS AND HEALING RATE 
С¡met id ine 
age (yr) 
ma le/female 
duration of disease (yr) 
Billroth I/Bill roth II anastomosis 
year after operation 
duration of present relapse (wk) 
basal acid output (meq/hr) 
peak acid output (meq/hr) 
serum gastrin (pg/ml) 
healed/not healed 
Data are presented as the mean + SEM 
* nine of 12 patients studied; ** eight of 9 patients studied 
48 
12 
14 
3 
9 
45 
2.3 
14.0 
48 
8 
+ 
/ 
+ 
/ 
+ 
+ 
+ 
+ 
+ 
/ 
4 
0 
3 
9 
2 
17 
1 .ι 
4. 
5 
4 
Q* 
1* 
Placebo 
42 
8 
15 
1 
8 
39 
2.1 
11 .0 
50 
1 
+ 
/ 
+ 
/ 
+ 
+ 
+ 
+ 
+ 
/ 
4 
1 
3 
8 
2 
11 
0.4** 
2.4** 
10 
8 
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Only 3 patients, 2 in the placebo group and one treated with Cimetidine, had 
also undergone vagotomy. There were no significant differences between the 
groups for age, sex, duration of disease or current relapse, incidence of 
BI or BII anastomosis, fasting serum gastrin levels, or gastric acid secre­
tion. All patients had fasting serum gastrin levels within the normal range 
at the time of entrance in the trial (normal <115 pg/ml). Nevertheless, one 
patient (the only female) subsequently had slightly elevated serum gastrin 
levels (160 pg/ml), with marked increases after administration of calcium 
and secretin suggestive of the Zollinger-Ellison syndrome (7). Her ulcer did 
not heal on placebo. After 4 weeks of treatment, ulcers in 8 of 12 cimetidine-
treated patients were healed, compared with one of 9 patients receiving placebo 
(p <0.05). Analysis of duration of disease, current relapse, or gastric acid 
secretion revealed no difference between patients whose ulcers were healed 
and patients whose ulcers did not heal. Data for ulcer symptoms are shown in 
figure 1. Symptoms were analyzed as days and nights with ulcer pain. The 
symptoms in the week before the trial were not significantly different between 
the 2 groups of patients. Both Cimetidine- and placebo-treated patients ex­
perienced marked relief of ulcer symptoms during the trial. There was a sig­
nificant improvement of day symptoms in the 2nd, 3rd, and 4th treatment week 
compared with day symptoms in the week before the trial in the cimetidine-
treated patients (p <0.05, ρ <0.02, ρ <0.02) which was achieved only in week 
4 in placebo-treated patients (p <0.05). The improvement in night symptoms 
was significant in all 4 treatment weeks compared with the symptoms in the 
week preceding the trial in cimetidine-treated patients (ρ <0.02, ρ <0.02, 
ρ <0.01, ρ <0.01) and in week 1, 2 and 3 of placebo treated patients (p <0.05, 
ρ <0.01
>
 ρ <0.02). Cimetidine-treated patients experienced significantly more 
pain-free nights in the 3rd and 4th treatment week than those who were on 
placebo (p <0.02). There was no difference in ulcer symptoms between patients 
whose ulcers healed and patients whose ulcers did not heal after 4 weeks in 
each treatment group. Data for antacid consumption are given in table 2. 
Table 2 ANTACID CONSUMPTION 
week 1 week 2 week 3 week k 
(tablets per week, mean + SEM) 
Cimet id ine 8 + 4 5 + 3 5 + 3 5 + 3 
Placebo 1 9 + 8 2 1 + 9 1 9 + 6 17 + 5 
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Fig 1 The effect of Cimetidine and placebo on ulcer symptoms expressed 
as days (top panel) and nights (bottom panel) with ulcer symptoms 
a week, in the week prior to the trial (week -1) and the 't weeks of 
the trial (week 1-A). Arrow indicates start of treatment. p-Values 
indicate statistical difference of concerning treatment week compared 
with the week prior to the trial (week - 1 ) . 
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Cimetidine-treated patients consumed fewer antacids than those on placebo, 
but none of the differences was statistically significant. During the trial, 
no side effects were reported. Only slight transient elevation of serum 
creatinine levels was seen in 2 patients on Cimetidine and one on placebo; in 2 
cimetidine-treated patients, a transient rise above normal SGPT was seen. 
No other changes in blood and urine were observed. 
After completion of the trial, all patients whose ulcers were not healed 
were treated with an additional course of 1 g Cimetidine daily. After 4 weeks, 
3 of the 4 Cimetidine failures and 5 of the 8 patients whose ulcers did not 
heal on placebo had healed ulcers. In the remaining 4 patients, ulcers healed 
after 2, 4, 5, and 10 months of treatment with Cimetidine, respectively; all 
were symptom free long before their ulcers healed. No relation between acid 
output and ulcer healing was found. All patients whose ulcers healed entered 
an open maintenance treatment study with 400 mg Cimetidine after breakfast 
and at bedtime. Two patients were lost to follow-up. Up to this time, of the 
19 patients treated for one year or longer, 3 have had a relapse, clinically 
confirmed by endoscopy. Of the 16 patients who did not relapse, 12 underwent 
repeat endoscopy after one year of treatment and were found to have no ulcer. 
Discussion 
This study shows, as our preliminary data already suggested (6), that 
Cimetidine promotes healing and alleviates symptoms of anastomotic ulcers 
after partial gastrectomy. Only one double-blind study on the effect of 
Cimetidine in patients with recurrent ulcer after gastric surgery has pre-
viously been reported (8). That study did not show a better healing of such 
ulcers by Cimetidine compared with placebo, but only 3 antrectomized patients 
were in the heterogeneous group of subjects studied.The proportion of healed 
ulcers with Cimetidine in our study (67%) is lower than that in most duodenal 
ulcer trials (>80%). Similarly, the proportion of ulcers healed on placebo 
(11%) is lower than that reported in duodenal ulcer (25-60%) (4-6). This 
demonstrates the lower tendency of anastomotic ulcers to heal spontaneously. 
After 4 and 8 weeks of Cimetidine treatment, the ulcers in 67% and 86% of the 
patients, respectively, had healed. This suggests that a longer treatment 
course may be indicated in this condition. In 3 patients with long histories 
(13-41 year) and with large ulcers who were totally symptom free during 
Cimetidine treatment, we saw the ulcers gradually decrease while it took 
months before they were healed. From this study, we cannot conclude whether 
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prolonging treatment is more effective than increasing the dose of Cimetidine 
in patients with delayed ulcer healing. 
Results of maintenance treatment in the present study are promising, 
although the numbers of patients were relatively small and the study was 
not double blind. Relapse rate was only 16% in one year, even though this type 
of ulcer is notorious for a high tendency to relapse (3). This study of long-
term Cimetidine treatment, however, does not allow us to draw conclusions 
about the need for or the best type of long-term treatment in patients with 
anastomotic ulcers after partial gastrectomy. 
Now that the efficacy of Cimetidine has been shown in these patients, 
studies comparing Cimetidine with other treatment regimens, either medical 
or surgical, are indicated. 
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Abstract 
Twenty patients with endoscopic evidence of severe ulcerative reflux oeso­
phagitis were treated with Cimetidine, 1.6 g daily, or placebo, in a double 
blind controlled trial. After 8 weeks 6 out of 13 Cimetidine treated patients 
were healed and one out of 7 patients on a placebo (p = 0.18). During the 
treatment symptom relief was not significantly different in Cimetidine in 
comparison to placebo treated patients. In those patients healed on Cimeti­
dine during the trial however, symptomatic response was significantly better 
compared to the unhealed patients on Cimetidine and those on placebo.Gastric 
acid output did not differentiate between responding and non-responding 
patients. Healing rate with Cimetidine was not improved by prolonged treat­
ment. During one year maintenance treatment with ΊΟΟ mg Cimetidine twice 
daily 6 out of 7 patients suffered relapse oesophagitis. 
It has been concluded that short term Cimetidine treatment of severe 
ulcerative reflux oesophagitis was beneficial in approximately 50% of the 
patients only. Since this severe oesophagitis tends to relapse in spite of 
low dose Cimetidine maintenance therapy, the main advantage of this treat­
ment is preparation for more definite measures, e.g. surgery. 
Introduction 
Cimetidine is an effective inhibitor of gastric acid secretion. Gastric 
acid is supposed to play an important role in the pathogenesis and the symp­
tomatology of reflux oesophagitis (1,2). Therefore we studied the effect of 
treatment with Cimetidine on healing and symptoms of reflux oesophagitis in 
a controlled double blind study. As reflux oesophagitis after cessation of 
medical treatment tends to relapse (3), we subsequently studied the effect 
of open maintenance treatment with Cimetidine in all healed patients. 
Patients and methods 
Twenty-three patients with evidence of severe ulcerative reflux oesophagi­
tis at endoscopy immediately prior to entrance in the trial were studied. In 
none of the patients and oesophageal stricture was present. The patients were 
treated as out-patients and were randomly allocated to Cimetidine, 400 mg af­
ter meals and at bedtime, or matching placebo during 8 weeks. They were free 
to use Gaviscon tablets (260 mg alginic acid, 260 mg sod. alginate, 260 mg 
magn. trisilic, 104 mg alum. hydr. colloid, 88.5 mg sod. bicarbonate per 
tablet) in case of heartburn symptoms. No other drugs were prescribed and 
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no other measures were taken during the trial. In 17 patients a standard 
gastric analysis before and after 6 pg/kg pentagastrin i.m. was performed 
before the study. Diary cards were used by each patient to record day and 
night heartburn symptoms and the number of Gaviscon tablets used. Patients 
were seen at bi-weekly intervals and at each visit they were asked for 
symptoms and side effects, diary cards were checked and routine haematologi-
cal and biochemical blood studies and urinalysis were performed (haemoglobin, 
haematocrit, red blood cell count, total white blood cell count, differential 
and platelet count, creatinine,urea, uric acid, bilirubin, alkaline phospha-
tase, SGOT and SGPT). 
Data about symptoms before treatment were obtained from the patients 
history. Symptomatic effect of treatment during the trial was analysed as 
days and nights without heartburn from the diary cards. After 8 weeks of 
treatment endoscopy was repeated and oesophagitis was recorded as healed 
or unhealed. Oesophagitis was considered healed only if at endoscopy no 
mucosal lesions were seen. 
All patients with unhealed oesophagitis were treated with additional 
open courses with Cimetidine 1.6 g daily and endoscopy was repeated every 
8 weeks. If no healing occurred after 16 weeks treatment with Cimetidine, 
the treatment was judged as a failure. 
Patients with healed oesophagitis entered open long term maintenance 
treatment with Cimetidine 400 mg after breakfast and at bedtime. Endoscopy 
was repeated in case of recurrent symptoms or after one year treatment in 
patients who remained free of symptoms. 
For statistical analysis Student's t-test and Fisher's exact test were 
used. 
Results are expressed as mean +_ 1 SEM. 
Results 
Three patients were withdrawn from the final analysis because of lack of 
cooperation, refusal of repeat endoscopy and co-existent oesophageal carci-
noma. Characteristics of the remaining 20 patients are given in table 1. 
Thirteen patients were treated with Cimetidine and 7 with placebo. There 
was no statistically significant difference between the 2 treatment groups 
regarding age, duration of disease and gastric acid secretion. Seven patients 
in the Cimetidine group were female compared to one treated with placebo. 
After 8 weeks 6 out of 13 Cimetidine treated patients compared to one out 
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(π = 13) 
60 + 5 
6 / 7 
6 + 2 
0.7 + 0 . 4 * 
8.9 + 2 . 5 * 
(η = 7) 
46 + 6 
6 / 1 
8 + 3 
2.1 + 1.3** 
11.2 + 3 . 1 * * 
of 7 on placebo were healed (p = 0.18; ns). Three out of the 6 with Cimeti­
dine healed patients were female (ns). 
Table 1. PATIENT CHARACTERISTICS, HEALING RATE AND PRE-TRIAL SYMPTOMS. 
Cimetidine Placebo 
age (yr) 
male/female 
duration of disease (yr) 
basal acid output (mmol H /h) 
maximum acid output (mmol H /h) 
healed (male/female) 6 (3/3) 1 (1/0) 
pre-trial symptoms: 
-days per week with pain 4.7 +_ 1 5.2 +_ 1.2 
-nights per week with pain 3.7 ¿ 1 5.0 + 1.2 
Data are presented as the mean + SEM 
* ten out of 13 patients studied; ** six out of 7 patients studied 
Symptoms before treatment were not different in both treatment groups 
(table 1). During the trial one patient in the Cimetidine group and one 
on placebo did not record their symptoms properly and they were excluded 
from the symptom-analysis. In the remaining 18 patients there was no dif-
ference between the Cimetidine and the placebo treated groups, neither for 
days nor for nights without symptoms (figure 1). 
Only 4 patients in the Cimetidine group and 4 in the placebo group 
used Gaviscon tablets during the trial. As in these patients the mean num-
ber of tablets consumed per day was less than one, these data were not ana-
lysed. 
The patients in the Cimetidine group were divided in 2 sub-groups: those 
who healed and those who did not heal during the trial. If the symptoms of 
these 2 sub-groups and of placebo treated patients were analysed a devia-
ting picture was seen. The number of symptomfree days and nights in patients 
healed on Cimetidine during the trial was significantly higher in all treat-
ment weeks (p <0.05 to ρ <0.001) in comparison to patients unhealed by 
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Cimetidine. Compared to patients on placebo patients healed with Cimetidine 
experienced significantly more painfree days in week 5,6,7 and 8 of treat­
ment (p <0.05) and more painfree nights in week 6 and 8 (p <0.05). During 
the whole trial period no significant differences were observed between the 
symptoms of the Cimetidine resistent patients and the symptoms of the place­
bo group (figure 2). 
In the week prior to the trial the number of days with heartburn symptoms 
in the patients healed on Cimetidine was 3.5 + 1.6 and in those unhealed 
5.0 + 1.3; the number of nights with symptoms was 2.3 +_ 1.5 and 4.3 + 1.2 
respectively. Collation of pre-trial symptoms in the Cimetidine healed and 
unhealed group, and in the placebo group revealed no statistical differences. 
Gastric acid secretion of patients healed by Cimetidine (BAO 1.0 + 0.6 
+
 +
 — 
mmol H /h; MAO 7.6 + 2.8 mmol H /h; η = 6) was not different from those not 
healed on Cimetidine (BAO 0.3 + 0.1 mmol H+/h; MAO 10.8 + 5.0 mmol H+/h; 
η = 4). 
After the tria¡ all unhealed patients were treated with subsequent open 
courses of Cimetidine. After 8 weeks one patient from the Cimetidine group 
and 2 from the placebo group showed healed oesophagitis. After 16 weeks one 
additional patient of the placebo group achieved remission. In total 10 pa-
tients healed during Cimetidine treatment, one healed on placebo and 9 pa-
tients did not respond to treatment. Gastric acid secretion of non-responding 
patients (BAO 1.5 + 1.3 mmol H+/h·, MAO 10.4 + 4.0 mmol H+/h; η = 6) was not 
different from patients responding to Cimetidine therapy (BAO 1.1 + 0.4 
mmol H+/h; MAO 9.3 + 2.1 mmol H+/h; η = 10). 
All 11 healed patients entered open maintenance treatment with 400 mg 
Cimetidine after breakfast and at bedtime. Four patients were lost to follow-
up. Of the remaining 7 patients 6 suffered endoscopically proven relapse 
oesophagitis during one year treatment. All relapses except one were sympto­
matic. The patient who did not relapse during this year was previously healed 
by placebo. 
No side effects were reported during the trial and during maintenance 
treatment. Only slight transient elevations of serum creatinine levels were 
seen in 3 Cimetidine and 2 placebo treated patients. No other changes in 
blood and urine parameters were observed. 
Discussion 
Various investigators reported different results of treatment with 
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.-a placebo η « 6 
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Fig 1 The effect of treatment with Cimetidine (solid line) and placebo 
(broken line) on heartburn symptoms,expressed as painfree days (upper 
panel) and nights (lower panel) a week, during the 8 weeks of the 
trial. Data are presented as the mean +_ SEM. 
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Fig 2 The effect of trial treatment on heartburn symptoms expressed as pain-
free days (upper panel) and nights (lower panel) a week in patients 
healed with Cimetidine (solid line), in patients not healed with Cime­
tidine (broken line) and placebo treated patients (dotted line) during 
the 8 weeks of the trial. Data are presented as the mean + SEM. Aste­
risks indicate data significantly different from patients healed on 
Cimetidine (p<0.05)o 
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Cimetidine in gastro-oesophageal reflux disease (3-6). Most studies showed 
a significant effect of Cimetidine on symptoms compared to a placebo while 
no significantly better healing of oesophagitis occurred (3,4,5). In only 
some of these studies improved healing as well as substantial symptom re-
lief by Cimetidine was reported (4,6). In all these studies patients with 
different grades of oesophagitis were included. There is only one report of 
Cimetidine treatment in which solely patients with severe ulcerative oesopha-
gitis were included. In this study oesophagitis improved significantly whereas 
symptoms did not. In these patients, however, an oesophageal stricture was 
present which might have influenced the results (7). In our study Cimetidine 
was not superior to a placebo in the healing and alleviation of symptoms of 
severe ulcerative reflux oesophagitis. This absence of significance in healing 
could be attributed to the single patient who healed on placebo. This was also 
the only patient who did not relapse during maintenance treatment. Thus beha-
viour of oesophagitis in this patient seems to be different from other 
patients. 
Healing rate with Cimetidine was about 50% and healing correlated well 
with symptomatic relief. Patients who responded well to the drug had rapid 
symptom relief whereas in others who did not respond symptom relief was ab-
sent. Prolonging treatment, as suggested by others (4) did not improve the 
effect of Cimetidine. 
We have not been able to define criteria to differentiate between the res-
ponders and non-responders to Cimetidine. Gastric acid output certainly was 
not useful, as this was not different between healed and unhealed patients. 
Apparently, gastric acid does not always play a key role in this condition 
and other factors are of varying aetiological importance. It may be assumed 
that gastric acid secretion was sufficiently inhibited by the dose of Cimeti-
dine used in these patients. It is therefore not likely that an increase of 
the dose will improve the chance of healing. 
This report presents also data on the effect of maintenance treatment with 
low dose Cimetidine to prevent recurrent oesophagitis. Although the number of 
patients was small and treatment was not double-blind the outcome was clear: 
Cimetidine in a dose of 800 mg daily does not prevent relapse of severe ulce-
rative reflux oesophagitis. From this study we cannot conclude whether a 
higher maintenance dose is suitable to prevent relapses. 
In conclusion Cimetidine was not superior to a placebo in the short term 
treatment of severe ulcerative reflux oesophagitis. Yet some patients respond 
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well to Cimetidine therapy. Since symptomatic relief in these patients is 
rapid, an attempt with Cimetidine seems indicated in patients resistant to 
other forms of medical therapy. However, since this severe form of oesopha-
gitis tends to relapse and recurrence is not prevented by low dose Cimetidine, 
subsequent surgical treatment, if feasible, will usually be indicated. 
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Abstract 
Continuous treatment of 3 Zol1 inger-El 1¡son patients with histamine H„-
receptor antagonists for ]k, 26 and 31 months resulted in effective relief 
of complaints and marked reduction in gastric acid secretion. In one of the 
patients the dose of Cimetidine had to be doubled after 15 months of treat-
ment because of a rise in basal gastric acid secretion accompanied by recur-
rent diarrhea. Fasting and secretin stimulated serum gastrin levels were not 
affected by long-term treatment with histamine H -receptor antagonists. No 
side-effects were observed in the 3 patients on long term treatment. 
Introduction 
Histamine hL-receptor antagonists have proved to be potent inhibitors of 
pentagastrin stimulated gastric acid secretion (1). These drugs have therefore 
been used in the treatment of hypersecretion of gastric acid in patients with 
the Zollinger-Ellison syndrome (2-8). 
Reports on long term efficacy of ^ -receptor antagonists, however, are 
conflicting (9,10). Bonfils et al (9) found partial reduction in efficacy in 
one and total inefficacy in 5 out of 10 cases with Zollinger-Ellison syndrome 
treated for 15-190 days. McCarthy et al (10) on the other hand, found hista-
mine h^-receptor blocking agents effective in all 7 Zollinger-Ellison patients 
treated for one to 15 months. 
In this study we report on the effect of long term treatment with histamine 
H?-receptor antagonists on basal gastric acid secretion, fasting and secretin 
stimulated serum gastrin concentrations and clinical symptoms in 3 Zollinger-
Ellison patients during continuous treatment for 14, 26 and 31 months. 
Patients and methods 
In all 3 patients the diagnosis of Zollinger-Ellison syndrome was based 
upon basal gastric hypersecretion (12-67 mmol/hr), fasting hypergastrinaemia 
(340-595 pg/ml), serum gastrin responses of at least 50% of basal value both 
to calcium, 15 mg/kg/3 hr and to secretin GIH (GIH Laboratories, Karolinska 
Institutet, Stockholm, Sweden), 1 CU/kg/30 sec and postprandial increases in 
serum gastrin of less than 50% of basal level (fig 1 and table 1). All 3 
patients originated from families with multiple endocrine adenomatosis type I. 
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T a b l e 1 EFFECT OF LONG TERM T R E A T M E N T WITH HISTAMINE H 2 - R E C E P T O R A N T A G O ­
NISTS ON FASTING AND SECRET IN-STIMULATED SERUM GASTRIN LEVELS IN 
3 PATIENTS WITH Z O L L I N G E R - E L L I S O N SYNDROME 
Case 
1 
2 
3 
Date 
1/6/75 
8/27/75 
11/19/76 
6/27/77 
8/12/75 
9/9/75 
5/11/77 
7/25/75 
5/13/77 
Treatment 
-
metiamide ΊΟΟ mg 
Cimetidine ^00 mg 
Cimetidine ^00 mg 
-
metiamide 200 mg 
Cimetidine kOO mg 
-
Cimetidine ΊΟΟ mg 
0 
595 
810 
755 
820 
340 
340 
330 
't Ίο 
330 
serum gastrin (pg/m 
+5 mi π 
1,300 
1,680 
1,450 
1,630 
910 
1,440 
1,450 
990 
1,010 
+10 min 
990 
1,450 
1,015 
1,310 
715 
990 
1,040 
820 
890 
I) 
+15 min 
760 
1,150 
875 
890 
530 
740 
770 
630 
590 
Secretin (G IH-laborator¡es, Karolinska Institutet, Stockholm, Sweden) in a 
dose of 1 CU / k g / 3 0 sec, was administered intravenously at time 0, co r r e s -
ponding to 2 hours after the oral intake of the drug. 
Case report 
Case 1: a 40-year old man had suffered from diarrhea and weight loss since 
1965. In 1974 a diagnosis of Zollinger-Ellison syndrome and presumptive hyper-
parathyroidism was made. From January>1974 to March,1975 the patient was 
treated with high doses of anticholinergic drugs resulting in only moderate 
relief of diarrhea. In March,1975 a treatment with metiamide was started. 
Case 2: a 39-year old woman had 3 pancreatic ß-islet cell tumors re-
sected in 1954. In 1968 3 hyperplastic parathyroid glands were resected 
for hyperparathyroidism. Since 1967 she had suffered from recurrent duodenal 
ulcers and diarrhea. In 1975 a diagnosis of Zollinger-Ellison syndrome was 
made. Treatment with metiamide was started in August,1975. At that time the 
patient had diarrhea but no active duodenal ulcer. 
Case 3: a 38-year old woman had suffered from gastric pain, heartburn, 
diarrhea and weight loss since 1972. In 1975 a diagnosis of Zollinger-Ellison 
syndrome and presumptive hyperparathyroidism was made. From March,1976 to 
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6 0 -
5 0 
4 0 
3 0 
2 0 -
1 0 -
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pg/ml 
70O-
600-
50O-
400-
300-
200-
100-
_ 
2 0 0 
• 
2 0 0 
• 
2 0 0 
• 
2 0 0 
• 
2 0 0 
• 
4 0 0 
• 
4 0 0 
• 
4O0mg 
• 
π η Π Π 
Σ - » υ » ζ - ϊ Σ Σ - ^ v ) 
1975 1976 
S О 0 3 
4 Σ Σ A 
1 9 7 7 
B A O 
m m o l / h 
Ό 
7 0 -
60-
5 0 -
4 0 -
3 0 -
20-
10 
Serum gastrin 
p g / m l 
7 0 0 -
6 0 0 -
5 0 0 -
4 0 0 
3 0 0 
2 0 0 
100H 
Cimetidine 4 0 0 400 4 0 0 400 400mg 
• • • 
i l l 
1976 
с t > 
I I I 
1977 
F i g 1 The e f f e c t o f l o n g t e r m t r e a t m e n t w i t h h i s t a m i n e Η - r e c e p t o r a n t a g o ­
n i s t s on b a s a l g a s t r i c a c i d s e c r e t i o n and s e r u m g a s t r i n i n 3 p a t i e n t s 
w i t h Z o l l i n g e i — E l l i s o n s y n d r o m e . The u p p e r d i a g r a m r e p r e s e n t s c a s e 1 , 
t h e m i d d l e c a s e 2 and t h e l o w e r c a s e 3 . 
44 
August, 1976 she was treated with high doses of anticholinergic drugs resulting 
in only moderate relief of complaints. In August 1976 treatment with Cimeti-
dine was started. At that time the patient had severe diarrhea and an active 
postbulbar ulcer. 
Gastric aspiration was performed as described by Hector (11). Gastric acid 
was determined by titration of gastric juice with 0.1 N NaOH up to pH 7.0. 
The basal gastric acid output was measured after discontinuing the drug for 
36 hours and also between one and 2 hours after the oral intake of the 
histamine H?-receptor antagonist. In case 1 the basal gastric acid secretion 
was also measured during intravenous infusion of metiamide (fig 1). 
Serum gastrin concentrations were measured by radioimmunoassay (12). Venous 
blood was drawn after an overnight fast, immediately before gastric intubation 
or the ingestion of the drug. Serum gastrin levels using this assay were 
66+18 (SD) pg/ml in 100 normal controls and 70+20 pg/ml in 80 duodenal ulcer 
patients. Blood, liver and kidney toxicity tests were done biweekly in metia-
mide and every 4 weeks in Cimetidine treated patients. 
Results 
Case 1 was treated with 1.0 g of metiamide daily, 0.2 g after meals and 
0.4 g at bedtime from March,1975. In May,1975 the dose was increased to 2.0 
g daily, 0.4 g after meals, at bedtime and at midnight, because of a poor 
clinical response. This latter dose led to a marked relief of diarrhea, a 
decrease in fecal fat excretion from 32-15 g daily and a weight gain of 4 
kg within 5 months. From October, 1975 he suffered from recurrent attacks 
of abdominal pain with raised levels of amylase in blood and urine and a 
diagnosis of pancreatitis and gallstones was nade.In November,1975 metiamide 
was replaced by Cimetidine in the same dosage. In February,1976 liver tests 
showed partial biliary tract obstruction and at laparotomy an expanded gall-
bladder containing multiple small gallstones and an enlarged, nodular and 
firm pancreas were found. Choledochoduodenostomy and cholecystectomy were 
performed. A biopsy from the pancreatic body confirmed the diagnosis of 
pancreatitis but failed to reveal tumor lesions. About 3 months after 
surgery the patient developed overt pancreatic insufficiency and diabetes 
mellitus. Replacement therapy with pancreatic extract and insulin was started. 
At present, the patient is in a reasonable general condition without pain but 
with moderate diarrhea and steatorrhea of about 15 g daily. The basal gastric 
acid output, both without and with histamine H?-receptor antagonists and the 
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fasting serum gastrin levels are shown in figure 1. 
Case 2 was treated from August,1975 to November,1975 with 0.8 g of metia-
mide daily, 0.2 g after meals and at bedtime. From November,1975 to November, 
1976 she received 0.8 g of Cimetidine daily, resulting in complete disappea-
rance of diarrhea, a decrease in fecal fat excretion from 12-6 g daily and a 
weight gain of 2 kg. In November,1976 she experienced recurrence of diarrhea. 
Basal gastric acid output, both without and with Cimetidine, was found to be 
higher than previously (fig 1). For that reason the dose of Cimetidine was in-
creased up to 1.6 g daily, 0.4 g after meals and at bedtime, resulting in a 
complete disappearance of diarrhea. 
Case 3 was treated from August,1976 with 1.0 g of Cimetidine daily, 0.4 g 
after breakfast and 0.2 g after lunch, after dinner and at bedtime. This 
treatment resulted in marked relief of complaints, healing of the postbulbar 
ulcer after 6 weeks, a decrease in fecal fat excretion from 17-7 g daily and 
a weight gain of 7 kg within 10 months. Results of basal acid secretion, with 
and without histamine ^-receptor antagonists and fasting serum gastrin levels 
are shown in figure 1. 
The results of the gastrin responses to secretin GIH 1 CU/kg/30 sec, 
before and during treatment with ^-receptor antagonists are presented in 
table 1. 
Repeated laboratory tests did not show any hematological, renal or liver 
toxicity. None of the patients had gynecomastia, galactorrhea or elevated 
serum prolactin levels (less than 14 ng/ml ; normal value less than 20 ng/ml). 
Detailed study of the cellular and humoral immunology (mixed lymphocyte cul-
ture, skin tests, autoantibody production and serum immunoglobulin concen-
tration) in cases 1 and 2 after treatment with histamine ^-receptor antago-
nists for 25 and 20 months respectively, revealed no abnormalities (13). 
Comment 
This study shows that histamine H^-receptor antagonists are able to inhibit 
gastric acid secretion in Zollinger-Ellison patients for periods up to two and 
a half years. In one patient (case 2) the dose of Cimetidine had to be increa-
sed in order to maintain adequate inhibition of gastric acid secretion. This 
was not attributable to a reduction in efficacy but was found to be related to 
a rise in basal gastric acid output. Since fasting serum gastrin levels did not 
greatly change in this patient, an increased sensitivity of the parietal cells 
to gastrin might have been involved in the rise in gastric acid secretion. 
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Although no hard evidence for this suggestion is presented, it is supported 
by the finding that administration of metiamide to rats is ineffective in 
blocking pentagastrin-stimulated DNA-synthesis by the gastric mucosa (14). 
Basal gastric acid secretion did not markedly change in cases 1 and 3 and 
histamine H?-receptor antagonists were found to be effective in a more or 
less dose-dependent manner. Our results contrast with those of Bonfils et al 
(9) who found partial reduction in efficacy in one and total inefficacy in 
5 cases during administration of histamine H?-receptor antagonists for 
15-190 days. Furthermore, we did not observe a so-called "prolonged inhibi-
tion" of gastric acid secretion after withdrawal of metiamide or Cimetidine 
(15). Within 12 hours after withdrawal of the drug all 3 patients expe-
rienced a recurrence of diarrhea and gastric acid secretion was not found to 
be markedly reduced 36 hours after discontinuing the drug. 
Bonfils et al (9) also found that secretin was no longer capable of in-
creasing serum gastrin levels in 2 out of 5 Zollinger-Ellison patients 
on treatment with histamine Hp-receptor antagonists. In our 3 Zollinger-
Ellison patients on long-term treatment, neither the fasting serum gastrin 
level nor the serum gastrin response to secretin changed markedly (table 1). 
The clinical efficacy of the histamine Hp-receptor antagonists was ex-
cellent in cases 2 and 3. The efficacy of Cimetidine in case 1 was difficult 
to assess since this patient had concomitant pancreatic insufficiency. Metia-
mide was clinically effective, however, before the onset of pancreatitis and 
also during pancreatic insufficiency Cimetidine markedly reduced diarrhea in 
this patient. Although the diagnosis of pancreatitis was made during treat-
ment with histamine hU-receptor antagonists, we do not believe that this 
disorder was related to the drugs used. Co-existing abnormalities, such as 
hyperparathyroidism,gallbladder disease or pancreatic tumors, might have been 
involved in the pathogenesis of pancreatitis in this patient. Moreover, serum 
and urinary levels of amylase were repeatedly normal in the 2 other Zollinger-
Ellison patients on long term treatment. 
None of our patients had gynecomastia, galactorrhea or increased serum 
prolactin concentrations, as have been found by others (16-18). No adverse 
reactions of an immunological nature, as suggested previously (19), could be 
demonstrated by detailed immunological studies. 
In conclusion, histamine hL-receptor antagonists were effective in the 
long-term symptomatic treatment of our Zollinger-Ellison patients, without 
side-effects. Although it is clear that more patients have to be studied for 
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longer periods, our results show that long term treatment with histamine 
hL-receptor antagonists may be a valuable alternative therapy for total gas-
trectomy in the Zollinger-Ellison syndrome. 
Addendum 
At present, (January,1980) Cimetidine is still effective in all 3 
cases. 
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Abstract 
Twenty-two duodenal and 16 gastric ulcer patients were treated with 'tOO mg 
Cimetidine twice daily for one year after their ulcers had healed. No change 
in gastric acid secretion was observed before and after treatment in 20 
duodenal and 13 gastric ulcer patients. Similarly, the inhibitory effect 
of 200 mg Cimetidine on gastric acid secretion was unaltered in 11 duodenal 
and 6 gastric ulcer patients studied, and Cimetidine blood levels were un-
changed in 9 duodenal and 't gastric ulcer patients after this year. In 7 
duodenal and 6 gastric ulcer patients the serum gastrin response to a stan-
dard test meal before and after treatment was identical.Four duodenal ulcer 
patients and 3 gastric ulcer patients had endoscopically proven relapse ulce-
ration. At endoscopy after one year treatment no asymptomatic ulcers were 
found in 18 duodenal and 13 gastric ulcer patients. It is concluded that 
long term treatment with Cimetidine influences neither gastrin cell function 
nor parietal cell function nor its sensitivity to Cimetidine in duodenal and 
gastric ulcer patients. 
Introduction 
Treatment with Cimetidine is effective in duodenal ulcer disease (1,2,3). 
There is additional proof that maintenance treatment with low dose Cimetidine 
prevents duodenal ulcer relapse (4-9). In the prevention of gastric ulcer 
relapse Cimetidine seems equally effective (10,11). However, before mainte-
nance treatment with Cimetidine in peptic ulcer disease can be advocated, 
the safety of such treatment has to be ascertained. Although treatment with 
Cimetidine for short periods of time seems to be safe, side effects and after 
effects of such treatment on parietal and gastrin producing cells may become 
overt only during long term treatment. Furthermore, it has to be demonstrated 
that the metabolism of Cimetidine does not change with time resulting in lower 
blood levels of Cimetidine and less inhibition of gastric acid secretion. In 
duodenal ulcer patients some of these aspects have been studied (9,12-16). In 
gastric ulcer patients, however, no studies of this kind have yet been done. 
This study was undertaken to assess the effect of one year continuous 
treatment with Cimetidine on gastrin cell function, as determined by post-
prandial serum gastrin levels, and on parietal cell function, as assessed by 
basal and pentagastrin stimulated gastric acid secretion in duodenal and 
gastric ulcer patients. Furthermore the inhibition of gastric acid secretion 
by Cimetidine in relation to the blood Cimetidine concentrations was studied 
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before and after one year treatment. Finally, data on re-ulceration, side 
effects and endoscopy of asymptomatic patients after one year of treatment 
are presented. 
Patients and methods 
Thirty-eight peptic ulcer patients without prior gastric operation were 
studied; 22 had a duodenal and 16 had a gastric ulcer. One duodenal ulcer 
and 7 gastric ulcer patients were females. Mean age in duodenal ulcer patients 
was 4 8 + 4 year and in gastric ulcer patients 5 1 + 3 year (mean + SE). All 
patients had endoscopically proven healed ulcers before they started mainte-
nance treatment. Treatment with 400 mg Cimetidine after breakfast and 400 mg 
at bedtime was continued for one year. The patients were not allowed to use 
any other drug with known or supposed ulcerogenic properties and no antacids 
were used. The patients were not encouraged to change their smoking and 
drinking habits during the trial and no dietary advice was given. Patients 
were seen at bi-monthly intervals and at each visit a careful history was 
taken of ulcer symptoms and possible side effects. Further, blood was drawn 
for laboratory tests: haemoglobin, haematocrit, total and differential white 
blood cell counts, platelets, serum creatinine, alkaline phosphatase, SGOT 
and SGPT, and an urinalysis was performed. To test patient compliance at each 
visit a urine sample was examined on the presence of Cimetidine. The detec-
tion of Cimetidine in urine was carried out by thin layer chromatography 
(Smith,Kline and French laboratories, Welwyn Garden, England: personal commu-
nication). In case of relapse symptoms endoscopy was performed. Patients with 
relapse ulcers discontinued maintenance treatment with Cimetidine and were 
treated as judged appropriate. After one year treatment all remaining patients 
were re-endoscoped and treatment was stopped. Immediately before they started 
Cimetidine treatment several tests were undertaken in a number of patients. 
These tests were repeated one year later between 3 and 7 days after Cimetidine 
had been stopped. At repeat tests for gastric acid secretion and serum gastrin 
concomitant blood Cimetidine levels were assessed: these were all below the 
detection limit (<0.05 Ug/ml). 
- Gastric analysis was performed in 20 duodenal and 13 gastric ulcer patients. 
After an overnight fast a gastric tube was positioned according to the 
method as described by Hector (17). Four 15 minute basal secretory collec-
tions were obtained and subsequently four 15 minute samples were collected 
after injection of pentagastrin (6 yg/kg i.m.). Peak acid output was calcu-
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lated as the sum of the 2 consecutive highest 15 minute samples multiplied 
by 2. Hydrogen ion concentration (mmol H /1) was determined by titration 
with 0.1 N NaOH up to pH 7.0. 
- Gastric acid secretion after Cimetidine was determined in 11 duodenal and 
6 gastric ulcer patients. One hour after oral intake of 200 mg Cimetidine 
gastric analysis was performed as described above although here basal se­
cretion was measured during two 15 minute periods. This 30 minute result 
was multiplied by 2 in order to express as mmol H+/hour. 
- Blood Cimetidine concentrations were measured in 9 duodenal and 4 gastric 
ulcer patients. Venous blood samples were drawn 60, 90, 105 and 135 minutes 
after oral intake of 200 mg Cimetidine during gastric analysis. Heparinized 
whole blood was stored at -20 С and Cimetidine concentrations were deter­
mined by high pressure liquid chromatography as described by Randolph et 
al (18). Minimal detectable blood concentration by this method was 0.05 
yg/ml. All samples were assessed twice. 
- Serum gastrin levels were measured in 7 duodenal and 6 gastric ulcer patients. 
Levels were determined before breakfast and 15, 30, 45, 60, 90, and 120 
minutes after a test meal. This test meal consisted of one slice of white 
bread, 50 g cheese.one boiled egg,200 ml skimmed milk, containing in total: 
30 g protein, 20 g fat and 24 g carbohydrate. The integrated gastrin response 
(IGR) was calculated by determining the area under the curve of the gastrin 
concentrations after subtraction of the basal concentration. Pre-treatment 
samples were stored at -20oC and were analysed together with post-treatment 
samples in the same assay to avoid interassay variation. Serum gastrin levels 
were measured by radio-immunoassay using a rabbit antiserum (19,20). This 
antiserum raised against human gastrin I, 2-17 covalently coupled to bovine 
serum albumin, binds all known C-terminal gastrin components with an almost 
equimolar potency (21). In 137 normal subjects the serum gastrin level was 
39 + 15 pg/ml (mean + 1 SD) (range 10-86 pg/ml). 
For statistical analysis Wilcoxon's signed rank test for matched pairs and 
Mann Whitney U test were used as appropriate. 
Results 
Patent ащПіапсе 
No patient f a i l e d to attend any of the follow-up v i s i t s during maintenance 
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treatment. Bi-monthly urine Cimetidine checks were, with 14 exceptions (6%), 
in different patients, all positive. 
Gastri£ acid secretion and its inhibition by_cjmetKH.ne 
There was no difference between the pre- and post-treatment data neither 
in duodenal nor in gastric ulcer patients (fig 1). 
Serum jja¿tri£ 
In duodenal ulcer patients the fasting and meal stimulated serum gastrin 
levels before and after one year of treatment were not significantly different; 
the fasting levels being 42 + 5 and 47 +_ 5 pg/ml (mean + SE; ns) and the 
integrated gastrin response 5.8 + 0.8 and 6.1 +_ 1.4 ng/ml.120 min (mean + SE; 
ns) respectively. In gastric ulcer patients the fasting serum gastrin level 
before treatment was 4 2 + 7 pg/ml and after 58 + 11 pg/nl (mean + SE; ns); 
the integrated gastrin responses were 6.4 + 1.2 and 7.0 + 1.3 ng/ml.120 min 
(mean + SE; ns) (fig 2). 
jî looji ciniej:ic[ijie_level¿ 
There was no difference between the data of the duodenal and the gastric 
ulcer patients studied and so they were pooled. The mean Cimetidine blood 
level between 60 and 135 minutes after oral intake of 200 mg before treatment 
was 0.83 + 0.08 ug/ml and after one year 0.88 + 0.08 yg/ml (mean + SE). Mean 
peak blood levels were 1.05 + 0.10 and 1.11 + 0.10 yg/ml (mean + SE) respec-
tively. None of the differences between pre- and post-treatment blood Cimeti-
dine levels were statistically significant (fig 3). 
Rej_a£se^  £l£e£s 
During maintenance treatment 4 duodenal ulcer patients (18%) and 3 gastric 
ulcer patients (19%) suffered a relapse of ulcers as proven by endoscopy. 
Gastric acid secretion measured before treatment in relapse patients was not 
significantly different from non-relapse patients. Six relapse pa-
tients studied (3 with a duodenal and 3 with a gastric ulcer) showed no de-
creased inhibition of acid secretion 60 to 150 min after oral intake of Cime-
tidine compared to inhibition of acid secretion in 15 patients who did not 
relapse (fig 4). 
Sj jie_ef fееts_aj2d_l ab£ra t о ry e fΐ e£ts 
During treatment no side effects were reported. On laboratory screening 
only minor transient changes outside normal were identified. 
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^¡g 1 Gastric acid secretion, gastric acid secretion after 200 mg Cimetidine 
(mmol H /h; mean + SE) and resulting percentage of secretion inhibi-
tion (mean ^ SE) before and after one year treatment with Cimetidine in 
duodenal (upper panel) and gastric ulcer patients (lower panel). 
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Fig 2 Serum gastrin levels (pg/ml; mean + SE) fasting and in response to a 
test meal before and after one year treatment with Cimetidine in 7 
duodenal (top panel) and 6 gastric ulcer patients (bottom panel). 
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Fig Ц Percentage of inhibition of gastric acid secretion (mean + SE) by 
200 mg Cimetidine orally before treatment in 15 non-relapse and 6 
relapse patients. 
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Repeat_endoscopy 
Repeat endoscopy after one year treatment in 18 duodenal and 13 gastric 
ulcer patients who did not suffer a symptomatic relapse revealed no ulcers. 
Discussion 
The present study shows that one year treatment with Cimetidine does not 
influence gastric acid secretion. Other investigators reported similar fin-
dings in duodenal ulcer patients (4,13,16). This study shows that gastric 
acid secretion in gastric ulcer patients is also unaltered. Whatever mecha-
nism causes the relative hyposecretion of gastric acid in gastric ulcer pa-
tients, it was unchanged after one year treatment with Cimetidine while the 
ulcer remained healed. The basal and postprandial serum gastrin levels in 
duodenal and gastric ulcer patients were not influenced by one year treatment 
with Cimetidine. So far other reports on serum gastrin in duodenal ulcer pa-
tients after the long term use of Cimetidine have been conflicting (12,14,16). 
There are no other reports on serum gastrin in gastric ulcer patients after 
the long term use of Cimetidine. 
It might be assumed that possible after-effects of long term Cimetidine 
treatment on gastrin cell function and on parietal cell function will become 
manifest earlier in gastric ulcer patients than in duodenal ulcer patients 
due to the significantly lower gastric acid secretion after Cimetidine in these 
patients (3). Such an effect, however, was not demonstrated in either group of 
patients. Cimetidine remained effective during one year continuous treatment: 
blood levels of Cimetidine and inhibition of gastric acid secretion were un-
changed. 
There was no reduced inhibition of gastric acid secretion in patients who 
suffered a relapse ulcer during maintenance treatment compared to patients 
who did not relapse. 
Rune et al (22) could also not demonstrate a relation between inhibition 
of acid secretion, blood Cimetidine concentration and symptomatic effective-
ness of Cimetidine during short term treatment. 
In conclusion: maintenance treatment with Cimetidine for one year in duode-
nal and gastric ulcer patients was safe. No after effects or rebound phenomena 
after stopping the treatment were observed. The acid inhibitory effect of 
Cimetidine did not change. 
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Abstract 
Blood Cimetidine levels were measured up to 5 hours after oral intake of 
200 mg Cimetidine with breakfast in 13 duodenal, 5 gastric and 15 anastomo­
tic ulcer patients,, There were large inter-individual differences in results. 
The mean peak blood concentration was 1.1Ί+0.07 Mg/ml (range О.б^-КЭ^ yg/ml ), 
the mean period during which the blood concentration exceeded 0.5 Ug/ml was 
Ttl + H minutes (range 23-306 min) and the mean area under the Cimetidine 
blood concentration curve (AUC) was 166+8 yg.min.ml (range 96-280 
pg.min.ml ). Coefficient of variation of these parameters was 33?, '»З? and 
23% respectively. There were no significant differences in these parameters 
between non-operated patients and patients with a partial gastrectomy. In 
patients restudied after 2 to 5 months blood Cimetidine levels proved well 
reproducible; mean coefficient of variation of peak blood level was 8.5+2.^, 
of time during which blood levels exceeded 0.5 Уд/ml 7o6+2.5%, and of the AUC 
5.0+1.0%. 
There was no difference in peak blood levels, duration of blood level excee­
ding 0.5 yg/ml and blood Cimetidine AUC between patients healed after k weeks 
Cimetidine therapy and those who took longer to heal. Likewise, there was no 
evidence of lower blood Cimetidine concentrations in patients who relapsed du­
ring maintenance Cimetidine treatment compared with those who did not relapse. 
In conclusion: between-subject variations of Cimetidine blood concentra­
tion are large and intra-indivi dual reproducibility of blood levels is good. 
Cimetidine blood levels, however, do not correlate with the outcome of 
treatment with this drug in peptic ulcer patients. 
Introduction 
Cimetidine is effective in short and long term treatment of duodenal 
ulcer (1,2,3) and recurrent ulcer after partial gastrectomy (4). In the 
treatment of gastric ulcer the effect of Cimetidine is less obvious (5). 
Even in duodenal and recurrent ulcer after partial gastrectomy, however, 
not all patients benefit equally from Cimetidine therapy: after 8 weeks of 
treatment the ulcers in about 15 per cent of the patients do not heal (1,2) 
and the same percentage of patients suffer relapse ulceration during one 
year maintenance treatment with Cimetidine (3,4). The effect of Cimetidine 
on ulcer healing is probably entirely to be attributed to its gastric acid 
inhibitory capacity. According to several studies the inhibition of gastric 
acid secretion is directly related to the blood concentration of Cimetidine 
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(6,7,8). Other studies have shown that between-subject variations of Cimeti-
dine blood levels are considerable (9-12). This variation in blood Cimetidine 
levels, therefore, might influence the clinical response to treatment with 
Cimetidine. 
The aim of this study was to assess the between-subject variability and 
the within-subject reproducibility of blood Cimetidine levels. Furthermore, 
the usefulness of measurement of blood Cimetidine levels to predict the out-
come of treatment with Cimetidine was studied. This was done by retrospective 
analysis of the relation between the blood Cimetidine levels and the response 
to short and long term Cimetidine treatment in unoperated peptic ulcer pa-
tients and in patients with anastomotic ulcer after partial gastrectomy. 
Patients and methods 
Thirty-three patients with peptic ulcer disease were studied. Five patients 
had a gastric ulcer, 13 a duodenal ulcer and 15 a recurrent ulcer after par-
tial gastrectomy. These patients formed part of a group who approximately 2 
years prior to this investigation had been studied. At that time they were 
treated with Cimetidine (1 g daily for 4 weeks) in double blind and, if 
necessary, subsequent open treatment courses until the ulcer had healed 
(4,13). Thereafter all these patients entered open maintenance treatment with 
400 mg Cimetidine twice daily for one year. Of this group those patients avai-
lable were selected who had not healed after 4 weeks treatment and those who 
suffered a relapse ulcer during maintenance treatment. A control group was 
randomly selected from patients who healed within 4 weeks and did not relapse. 
In none of the patients renal function was impaired: serum creatinine levels 
were within normal limits in all patients (<100 ymol/1). 
After an overnight fast blood Cimetidine levels were measured before and at 
30, 60, 90, 120, 180, 240 and 300 minutes after ingestion of a 200 mg Cimeti-
dine tablet together with a standard breakfast. Whole blood Cimetidine concen-
tration was measured by high pressure liquid chromatography as described by 
Randolph et al (14). Hinimum detectable blood level by this method was 0.05 
pg/ml. The intra-assay precision, determined by the coefficient of variation 
of fivefold measurements of 3 blood samples with mean Cimetidine concentra-
tions of 0.24, 0.77 and 1.26 yg/ml, varied from 2.1 to 3.7%. The inter-assay 
coefficient of variation ranged from 2.1 to 7.0% for 4 consecutive determina-
tions of 3 blood samples with mean Cimetidine concentrations of 0.24, 0.71 
and 1.14 yg/ml. 
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Peak blood level, the time during which the blood concentration exceeded 
0.5 yg/ml and the area under the Cimetidine blood concentration curve (AUC) 
were determined. Inter-individual variation for all these parameters was 
calculated and this calculation was also made after these data had been cor-
rected for bodyweight and body surface area. Besides the correlation between 
the AUC and age was computed. 
To assess the intra-individual variation of Cimetidine concentrations 
blood levels were remeasured 2 to 5 months later in 7 out of the non-operated 
and 4 out of the patients with a partial gastrectomy according to the same 
protocol. 
Furthermore, Cimetidine blood levels in 12 non-operated patients were 
correlated with those obtained approximately 2 years prior to this study 
with a slightly different protocol. At that time blood concentrations were 
measured at 0, 60, 90, 105 and 135 min after 200 mg Cimetidine on a fasting 
stomach. 
Two duodenal, 2 gastric and 5 anastomotic ulcer patients had not healed 
after 4 weeks Cimetidine treatment and were designated as "non responders". 
All other patients responded to 4 weeks therapy. Blood Cimetidine levels in 
non-responding patients were compared with those in "responders". Four duo-
denal, 1 gastric and 4 anastomotic ulcer patients suffered a relapse ulcer 
during maintenance Cimetidine treatment. Blood Cimetidine levels in relapse 
patients were compared with those in patients who did not relapse. 
Inter-individual variation was expressed as the coefficient of variation. 
Intra-individual reproducibility was expressed as the mean of the coeffi-
cients of variation calculated for the 2 consecutive measurements in each 
patient. Regression analysis was done by the method of least squares. 
Comparison between groups was performed by Student's t-test. Data are 
presented as the mean + 1 SEM. 
Results 
Mean peak blood Cimetidine concentration in non-operated patients was 
1.13+0.08 pg/ml (range 0.54-1.80 vig/ml ; n=18). This level was reached 60 
minutes (range 30-120 min) after oral intake of the drug. In patients with 
a partial gastrectomy mean peak blood level was 1.15+0.10 yg/ml (range 
0.58-1.94 yg/ml; n=15) and this level occurred also after 60 minutes (range 
30-180 min). Mean duration of blood level exceeding 0.5 yg/ml was 145+15 
min (range 23-306 min) in non-operated patients and 137+14 min (range 58-271 
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min) in patients with a p a r t i a l gastrectomy. Mean area under the blood con­
centration curve in non-operated patients was 171+12 ug.min.ml (range 
96-280 yg.min.ml" ) and in patients with a p a r t i a l gastrectomy 161+11 
pg.min.ml (range 98-263 ug.min.ml" ) ( f i g 1). 
Blood Cimetidine concentrat ion 
(p.g / m l ) 
1.5-1 
• non operated ( η = 18) 
x χ a n t r e c t o m y (η = 15) 
240 3 0 0 
Time (minutes) 
Fig 1 Blood Cimetidine concentration (mean + 1 SEM) after 200 mg Cimetidine 
orally with breakfast in patients without gastric operation and pa­
tients with a partial gastrectomy. 
None of the differences between non-operated and antrectomized patients were 
statistically significant. The coefficient of variation was therefore calcu­
lated for the patients as one group. The coefficient of variation of peak 
blood level was 33%, of period of blood level exceeding 0.5 yg/ml 43% and of 
AUC 29%. If correction for bodyweight was made these coefficients of varia-
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tion were respectively: 34%, 36% and 28%, and corrected for body surface area 
they were 32%, 34% and 25% respectively. 
Correlation coefficient (r) of AUC with age was 0.40 (p<0.05). 
Cimetidine blood levels measured on 2 different occasions in non-operated 
patients and in patients with a partial gastrectomy were well reproducible. 
The mean coefficient of variation of the 2 determinations of peak blood 
levels was 8.5+2.4%, of period of blood levels exceeding 0.5 yg/ml 7.6+2.5% 
and of the area under the Cimetidine blood concentration curve 5.0+1.0%. 
Correlation coefficient (r) of the 2 measurements of peak blood level was 
0.91 (D<0.001); of duration of blood concentration exceeding 0.5 pg/ml 0.96 
(p<0.001) and of AUC 0.97 (p<0.001). The AUC measured on these 2 different 
occasions is presented in figure ?. 
AUC 
í.μg . m m . ml" ) 
300 
250 
200 
150 
Fig 2 Area under the blood Cimetidine 
curve (AUC, yg.min.ml ) measu­
red on 2 different occasions 
(I and II) in L* patients with 
a partial gastrectomy (x) and 
7 non-operated patients (·)= 
Correlation coefficient (r) of AUC in the 12 patients measured in this 
study and 2 years earlier was 0.77 (p<0.01). 
Peak blood level, period of blood level exceeding 0.5 цд/ті and area under 
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the blood concentration curve in patients with different clinical reaction 
to Cimetidine therapy are given in table 1. There were no significant dif-
ferences between responding and non-responding or relapsing and non-relap-
sing patients without previous gastric surgery. Likewise if data from duode-
nal and gastric ulcer patients were evaluated as separate groups, no signi-
ficant differences were seen. In patients with a partial gastrectomy there 
was no difference in peak blood level, period of blood Cimetidine concentra-
tion exceeding 0.5 yg/ml and AUC between responding and non-responding pa-
tients. In relapse patients these data were significantly higher than in non-
relapse patients (p<0.01). 
Discussion 
This study confirms that blood Cimetidine levels are highly variable in 
different individuals (9-12). The most variable parameter was the period 
during which the blood Cimetidine concentration exceeded 0.5 pg/ml. According 
to several studies 0.5 pg/ml is the blood concentration required to achieve 
50% inhibition of maximal acid output (7,15). 
Increase in bioavailability of Cimetidine with age has been reported (10, 
16). In our study correlation of AUC with age reached just statistical signi-
ficance. Age, however, accounts only partly for the large variations measured. 
Disparities to the same extent were also present in age contemporaries. From 
this study we cannot conclude what other factors cause these differences. The 
variations persisted after correction for body weight or body surface area. 
We did not find differences in Cimetidine blood levels, period of Cimeti-
dine blood concentration exceeding 0.5 pg/ml and time of occurrence of peak 
blood level between patients with an intact stomach and patients with a par-
tial gastrectomy. Partial gastrectomy, therefore, does not affect the absorp-
tion of Cimetidine. 
Cimetidine blood levels studied twice with 2 to 5 months interval were very 
well reproducible in non-operated patients as well as in patients with a par-
tial gastrectomy. Moreover, if compared to blood levels assessed 2 years ear-
lier Cimetidine concentrations were in the same range. This shows that within-
subject reproducibility of blood Cimetidine levels is good. 
On this basis we felt justified to evaluate the relation between data on 
blood Cimetidine levels measured in this study and previous reaction to Cime-
tidine therapy. No such correlation was found: peak blood levels, time during 
which the blood level exceeded 0.5 yg/ml and AUC were not lower in non-respon-
69 
Table 1 PEAK BLOOD CONCENTRATION, PERIOD OF BLOOD LEVEL EXCEEDING O.SpG/ML, AND AREA UNDER THE BLOOD 
CIMETIDINE CONCENTRATION CURVE IN PATIENTS WITH DIFFERENT CLINICAL REACTION TO THERAPY 
Responders Non-responders £ Non-relapse Rel apse 
Non-operated patients: 
peak blood concentration (pg/ml) 
period exceeding 0.5 pg/ml (min) 
area under the curve (yg.min.ml ) 
Antrectomized patients: n=10 n=5 n=11 n=4 
peak blood concentration (pg/ml) 1.14+0.12 1.17+0.22 ns 0.98+0.09 1.63+0J4 p<0.01 
period exceeding 0.5yg/nil (min) I'tS+U 127+37 ns 116+11 197+31 p<0.01 
area under the curve (yg.min.ml" ) 166+10 152+29 ns 140+7 219+15 p<0.01 
n=l4 
1.11+0.10 
145+18 
177+16 
n=4 
1.21+0.15 
143+30 
176+31 
ns* 
ns 
ns 
n-13 
1.14+0.10 
146+13 
171+13 
n=5 
1.11+0.17 
143+46 
172+29 
ns = statistically not significantly different 
All data are presented as the mean + 1 SEM 
ding or relapse patients. We have no explanation why blood levels in relapse 
patients with a partial gastrectomy were higher than in non-relapse patients. 
From this study we cannot conclude whether the amount of inhibition of gas-
tric acid secretion achieved by Cimetidine correlates with clinical response 
to therapy because inhibition of acid secretion was not measured. However, 
there are several observations that inhibition of gastric acid secretion by 
Cimetidine correlates well with the blood Cimetidine concentration (6,7,8). 
Yet, in one study no such correlation was found (12). In that study also no 
correlation was observed between the symptomatic effect of Cimetidine therapy 
and the inhibition of gastric acid secretion or Cimetidine blood levels (12). 
We conclude that within-subject reproducibility of Cimetidine blood levels 
is good in patients with an intact stomach as well as in patients after a 
partial gastrectomy. Between-subject variation of Cimetidine blood concen-
tration, however, is large. Nevertheless measurement of Cimetidine blood 
levels does not seem to be of clinical importance since there is no correla-
tion between Cimetidine concentrations and the outcome of treatment with 
Cimetidine in peptic ulcer patients. 
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CIMETIDINE DOES NOT ACCELERATE SKIN GRAFT REJECTION IN MICE 
HPM FESTEN, OHM BERDEN and RAP KOENE 
Department of Internal Medicine, Division of Gastroenterology and Nephrology, 
St. Radboud Hospital, Nijmegen, The Netherlands 
Published in: 
Clinical Experimental Immunology 40: 193, 1980 
73 
Abstract 
The influence of Cimetidine on skin graft rejection was studied in a well 
defined transplantation model of inbred mice. Four allogeneic transplantation 
combinations with increasing antigenic disparity and one xenograft combination 
were studied. Cimetidine (25 mg/kg body weight) was administered intraperi­
toneal ly at 8 hour intervals until rejection occurred. No differences in graft 
survival were observed between cimetidine-treated groups and saline-treated 
controls in any of the combinations studied. 
Introduction 
Cimetidine is a competitive antagonist of histamine on HL-receptors. Its 
main effect is a marked inhibition of gastric acid secretion and therefore 
it is widely used in clinical practice. As Τ lymphocytes bear ^-receptors 
(1-3) some concern has been raised about a possible influence of Cimetidine 
on the immune response. Inhibition of suppressor Τ cells by Cimetidine might 
result in an enhancement of delayed type hypersensitivity reaction, and some 
observations in vivo and in vitro support this hypothesis (4,5). Other 
studies, however, did not confirm these findings (6,7). The putative immuno-
stimulatory effect of Cimetidine is of considerable importance because 
Cimetidine has been used successfully in the prevention of upper gastro­
intestinal haemorrhage in renal transplant recipients (8). The cellular 
immune response which plays an important role in renal allograft rejection, 
might be enhanced by treatment with Cimetidine (9,10). 
The availability of many inbred mouse strains makes it possible to study 
graft rejection in donor recipient combinations of well defined antigenic 
disparity. We have taken advantage of this situation and have studied the 
effects of Cimetidine on skin graft survival in models with increasing 
antigenic differences. 
Materials and methods 
Mice 
Inbred lines of B10.D2/New Sn, BIO.A, BIO.Br, C57B110, and BIO.LP mice 
were originally obtained from the Jackson Laboratory, Bar Harbor, Maine, USA. 
Inbred PVG/c rats came originally from the Institute of Psychiatry, Bethlem 
Royal Hospital, Beckenham, Kent, U.K. These strains were kept by continuous 
brother-sister mating in our animal laboratory. 
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Ооп<эг-^есі£іеп^ ^^bjnations 
Infonnation concerning H-2 haplotypes and H-2 recombinants came from 
Festenstein and Demant (11) and concerning non-H-2 loci from Graff and 
Bailey (12). The 5 chosen conbinations and their antigenic disparity 
are listed in table 1. They were chosen so as to represent an increase in 
histoincompatibility; i.e. a number of weak non-H-2 differences;an H-2D 
difference;an H-2K difference; a complete H-2 complex disparity and a 
xenogeneic difference. 
j^ldn_graftjuij technique 
Donor tail skin was grafted onto the flank of the recipients by a modi­
fied "fitted graft" technique as described earlier (13). Skin grafts were 
inspected daily. 
Erü9_aiimlnÍsjLr£t:Íon. 
The recipients received intraperitoneal injections of 0.5 mg Cimetidine 
dissolved in 0.1 ml saline (25 mg/kg body weight) at 8 hr intervals until 
the skin grafts were rejected. Control animals were similarly treated with 
0.1 ml saline. 
Statist i £s 
Mean survival times in days were calculated for each group and differences 
between Cimetidine and control groups were compared by Student's t-test. 
Results 
There was no difference in graft survival time between the cimetidine-
and the saline-treated mice. Results for combinations with low antigenic 
disparity were not different from those for combinations with higher antigenic 
disparity (table 2). 
Discussion 
Rejection of skin grafts in the mouse is primarily a cellular phenomenon.Allo-
geneic and xenogeneic skin grafts in congenitally Τ cell-deficient, nude mice 
are accepted indefinitely (14,15), despite the fact that these mice are able 
to produce antibodies of both IgM and IgG class directed against the graft 
antigens (16). Skin graft experiments, therefore, offer the opportunity to 
study the influence of drugs on Τ cell function in vivo. Skin graft models 
are to be preferred because in the rejection of whole organ transplants humoral 
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Table 1 ANTIGENIC DIFFERENCES OF STRAIN COMBINATIONS STUDIED 
H-2 complex 
Donor -*· Recipient Haplotype Speci f ici ties Non-H-2-loci 
private pubi i с 
C57B110 * BIO.LP Ь -*• Ь Н-3; Н-13 and probably two others(17) 
BIO.Br -»• BIO.A к •* axb H-2D.32 H-2.7 
B10.D2 -* BIO.A d -»• axb H-2K.31 H-2.34 
B10.D2 •*• C57B110 d •* b H-2K.31 H-2.3,8,10,13,34,40, 
H-2D.4 41,42,43,44,47,49 
PVG/c + C57B110 xenogeneic graft 
Table 2 MEAN SKIN GRAFT SURVIVAL TIME IN CIMETIDINE AND SALINE TREATED GROUPS 
Donor •+• Recipient Mean survival time + SD(days) 
Cimetidine S a l ¡ n e 
C57B110 -»· B10.LP 
B IO.Br -* BIO.A 
B10.D2 -" S I C A 
B10.D2 -*· C57B110 
PVG/c -+ C57B110 
36.7 + Τ».О (13) 
18.0 + 3.3 (29) 
11.8 + 1.9 (29) 
13.0 + 1.9 (13) 
7.3 + 0.Ί (15) 
^З.І + 7.'t (10) 
18.0 + 3.2 (25) 
12.5 + 2.1 (25) 
13.5 + 2.1» (14) 
7.2 + 0.6 (15) 
* Student's t-test 
** number of mice in parentheses 
mechanisms probably play an important role (18). Moreover, skin grafting is 
a more sensitive method of detecting small changes in іплипе responsiveness 
(19,20). 
Our investigation shows that there was no influence of Cimetidine on the 
rejection of skin grafts in a well defined transplantation model of inbred 
mice, even if histoincompatibility was very weak. If there were any effect 
of Cimetidine on graft survival this would have become apparent especially 
in the group with the lowest antigenic differences. 
If Cimetidine has an influence on cellular immune responses it is probably 
mediated through a blockade of suppressor Τ cells. Increases in delayed hyper­
sensitivity reactions in man have been reported (4). On the other hand, it 
has been found that hL-blockers sometimes inhibit delayed hypersensitivity 
in guinea-pigs (21). The influence of Cimetidine on graft rejection in clini­
cal renal transplantation is also controversial. Controlled clinical trials 
are needed before definitive conclusions can be drawn. However, on the basis 
of our results in an experimental model we conclude that acceleration of 
graft rejection by Cimetidine is unlikely. 
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CHAPTER 9 
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Abstract 
The influence of Cimetidine on several immunological parameters was studied 
with 3 weeks interval in 9 patients with peptic disease, before, during and 2 
days after treatment with 1.6 g Cimetidine daily. 
No change was observed in the reaction to skin tests with candida albicans, 
mumps, trichophyton, intermediate strength purified protein derivative and 
varidase (streptokinase + streptodornase) in patients as compared to 11 con-
trols. Neither any change occurred in total lymphocyte counts, nor in results 
of lymphocyte transformation tests stimulated by phytohaemagglut¡nin, pokeweed 
mitogen or a cocktail of the antigens as used for skin testing. Results of 
mixed lymphocyte cultures (MLC) did not alter and showed also unchanged sti-
mulating and responding capacity of lymphocytes in one way M L C 
No difference was observed in IgG, IgA or IgM levels and all were in the 
normal range. 
Introduction 
Cimetidine is a competitive antagonist of histamine on Hj-receptors. Its 
main effect is a marked inhibition of gastric acid secretion and therefore 
it is widely used in clinical practice. As Τ lymphocytes bear H?-receptors 
(1,2,3) concern has arisen about the possible effects of Cimetidine treatment 
on the immune response. 
Inhibition of histamine receptor bearing Τ cells by Cimetidine might result 
in an enhancement of delayed type hypersensitivity reaction and some obser­
vations in vivo (4) and in vitro (5) support this hypothesis. Other studies, 
however, did not confirm these findings (6,7,8). 
Enhancement of cellular immune response by Hp-receptor antagonists in man 
would be of importance since Cimetidine is succesfully used in the prevention 
of upper gastrointestinal haemorrhage in renal transplant recipients (9). 
Graft rejection in renal transplantation is known to be mainly mediated by 
this type of reaction, and it is suggested that rejection might be increased 
by Cimetidine (10,11). We therefore studied the influence of Cimetidine on 
several immunological parameters in patients treated with Cimetidine for 
peptic ulcer disease. 
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Patients and methods 
^ t i e n t s 
Six nales and 3 females, age ranging fron 28 to 63 year, with peptic ulcer 
disease but otherwise healthy, entered the study after informed consent. 
None of the patients had been treated with Cimetidine before. 
Treatment 
Cimetidine 400 mg four times daily was started at day 3 of the study and 
stopped at day 40. Patients were instructed not to take any other drug during 
the study. Blood Cimetidine levels were assessed at day 21 and 42. This 
assessment was performed by high pressure liquid chromatography as described 
by Randolph et al (12). 
Methodjs 
The following studies were performed at day 0, 21 and 42. 
Lymphocyte count: lymphocytes were calculated from the total leucocyte and 
о 
differential counts and expressed as cell number χ 10 /1. Two hundred cells 
were differentiated on May-Grünwald stained smears. 
Lymphocyte transformation tests: lymphocytes were cultured according to 
5 
du Bois et al (13). Cell concentration was adjusted to 3 χ 10 /ml. Aliquots 
of 1 ml were cultured at 370C. PHA reactivity was determined by adding 25 pg 
phytohaemagglutinin(Welcome MR10, Beckenham, United Kingdom) and PWM reacti­
vity by adding 25 yg pokeweed mitogen (Gibco, New York, USA) to 1 ml lympho­
cyte suspension. Lymphocyte transformation by antigens was measured by means 
of a cocktail of antigens as described by Leguit et al (14). The cocktail 
contained 5 different antigens (PPD, varidase. Trichophyton antigen, candida 
albicans allergenic extract and mumps skin test antigen). Mixed lymphocyte 
cultures (MLC) were made by mixing 0.5 ml lymphocyte suspension from the 
patient, with 0.5 ml lymphocyte suspension from a healthy volunteer. Unilate­
ral stimulation was measured by blocking the lymphocyte suspensions one-way 
by preincubation at 37 С during 30 min. with mitomycin-C (Christiaans, 
Brussels .Belgium) at a final concentration of 15.4 ug/ml. The cultures with 
PHA were terminated on the 3rd day, all other cultures on the 6th day. To 
determine DNA synthesis 0.075 uCi C-thymidine (specific activity 6.25 
mCi/mmol, Amersham, United Kingdom) was added 24 hours before the cultures 
83 
were terminated. The lymphocytes were harvested on millipore microfibre 
glassfilters (Millipore Corp., Bedford, Mass., USA). The C-thymidine 
uptake in counts per min. (CPM) was measured in a liquid scintillation 
counter (LKB 81000). The cultures were carried out in triplicate under 
sterile conditions. For each lymphocyte transformation test a healthy volun-
teer served as control and the same subject served as control in all succes-
sive tests in one patient. Results of tests in patients were compared with 
those in controls and expressed as patient to control ratio, except in 
mixed lymphocyte cultures, the results of which were expressed as counts 
per minute. 
Immunoglobulin levels: quantitative levels of IgG, IgM and IgA in serum 
were estimated with an automated turbidimetric immunoprecipitation method (15). 
Skin tests: skin tests were performed by intradermal injection in the 
forearm of 0.1 ml of: candida albicans extract 0.5:100 (Bencard, U.K.), 
trichophyton allergenic extract 0.5:100 (Bencard, U.K.), intermediate 
strength purified protein derivative (PPD, 10 lU/ml, KIV, Bilthoven, The 
Netherlands), mumps skin test antigen (Lilly and Co, Indianapolis, USA) and 
varidase (10 1U streptokinase combined with 10 1U streptodornase; Lederle 
2 
Wayne, USA). Erythema and wheal size of skin tests were recorded as mm at 
24, 48 and 72 hours by one single observer. Maximum responses to each antigen 
before, during and after treatment were compared in each subject. An augmen-
tation of 100% or more was regarded an increased reaction and a reduction of 
2 
50% or more a decreased reaction. A reaction of 20 mm or more was considered 
to be a positive test. Negative tests which had become positive and positive 
tests, changed to negative, were judged as increased and decreased respecti-
vely. Results of skin tests negative on both occasions were discarded. Skin 
tests were also performed in a control group of 11 healthy volunteers at 
similar intervals. 
Statistics 
Results of differential counts, lymphocyte transformation tests and 
immunoglobulin levels were compared by Wilcoxon's rank sum test. Differences 
2 
of results in skin tests in patients and controls were analysed by X analy-
sis. 
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Results 
Blood levels of Cimetidine at day 21 were 1.30 + 0.29 yg/ml (mean + SE) 
and at day 42 nil in all patients. 
g 
The number of lymphocytes did not change and was 2.0 + 0.2 χ 10 /1 before 
treatment, 2.0 + 0.2 χ 109/l during treatment and 2.1 + 0.1 χ 109/1 (mean + 
SE) after treatment. 
Results of lymphocyte transformation tests stimulated by PHA and various 
antigens are shown in figures 1 and 2. Although a few patients showed changes 
in response, reactions in most patients remained unchanged and differences in 
results before, during and after treatment were not significant. A similar 
pattern was seen in by pokeweed mitogen stimulated cultures: median patient 
to control ratio of counts per minute was 1.01 before, 1.02 during, and 1.11 
after Cimetidine treatment. Mixed lymphocyte cultures and stimulating and 
responding capacity of patients-lymphocytes in one way MLC did not alter sig­
nificantly (figure 3). 
No change was observed in IgG, IgM or IgA levels and all were within the 
normal range (figure 4). 
The number of increased or decreased skin tests in Cimetidine treated pa­
tients were not significantly different from controls. As changes in erythema 
did not differ from those in wheal size only the latter are represented 
(table 1). 
Discussion 
This study did not reveal any influence of treatment with Cimetidine on 
the immunological parameters studied. Also no change was observed directly 
after the drug was discontinued and blood Cimetidine concentrations were nil. 
In contrast to Avella et al (4) we did not find a more pronounced increase in 
skin test reactivity in patients on treatment with Cimetidine compared to 
controls. Moreover, the results of lymphocyte cultures stimulated by a 
cocktail of the antigens used for skin testing, which correlate well with 
skin tests (14) corroborated this observation. Also 2 other Τ cell tests: 
phytohaemagglutinin stimulation and responding capacity in one way MLC did 
not show any change. In a previous study, in mice treated with Cimetidine, 
we also could not demonstrate an increase of cellular immune response (8). 
Changes in Τ cell function induced by Cimetidine are therefore unlikely. 
Likewise В lymphocyte function, as tested by pokeweed mitogen stimulation 
and determination of immunoglobulin levels, did not show any difference. 
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patient 
control 
ratio of 
CPM 
O' median 
before during after 
Cimetidine treatment 
Fig 1 The e f f e c t of treatment 
w i t h C imet id ine on phytohaemag-
g l u t i n i n induced lymphocyte 
t r a n s f o r m a t i o n . Data are ex­
pressed as p a t i e n t to c o n t r o l 
r a t i o o f counts per minute(CPM). 
Each l i n e represents observa­
t i o n s in one p a t i e n t - c o n t r o l 
pai r. 
3 
patient 
control 
ratio of 
CPM 
О = median Fig 2 The e f f e c t of t reatment 
w i t h C imet id ine on lymphocyte 
t r a n s f o r m a t i o n induced by a 
c o c k t a i l of 5 a n t i g e n s . Data 
are expressed as p a t i e n t to 
c o n t r o l r a t i o of counts per 
minute (CPM). Each l i n e r e p r e ­
sents o b s e r v a t i o n s in one pa­
t i e n t - c o n t r o l p a i r . 
before during after 
Cimetidine treatment 
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MLC 
5 0 0 0 
counts/mm 
1000-
bilateral 
stimulating 
capacity 
responding 
capacity 
before during after 
Cimetidine treatment 
Fig 3 The effect of treatment with Cimetidine on lymphocyte transforma­
tion in bilateral mixed lymphocyte cultures (MLC) and on stimula­
ting and responding capacity in one way MLC. Data presented are 
the median of observations in 9 patients expressed as counts per 
mi nute. 
U/hi 
150-
100 
50 
τ 
I 
IgM 
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IgG 
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J Fig 't The effect of treat­
ment with Cimetidine 
on immunoglobulin le­
vels. Data presented 
are the mean +_ SEM of 
observations in 9 
patients. 
before during after 
Cimetidine treatment 
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Table 1 EFFECT OF CIMETIDINE TREATMENT ON SKIN TESTING 
Cimetidine treatment before versus during 
С in. cont. ** 
со 
mumps : 
candida albicans: 
P.P.D. : 
trichophyton : 
varidase : 
total : 
η 
increased 
decreased 
η 
increased 
decreased 
π 
i ncreased 
decreased 
η 
increased 
decreased 
η 
i ncreased 
decreased 
η 
increased 
decreased 
9 
3 
1 
6 
2 
0 
5 
k 
0 
9 
5 
1 
8 
5 
0 
37 
19 
2 
11 
2 
5 
3 
3 
0 
7 
k 
0 
11 
6 
1 
9 
6 
0 
ill 
21 
6 
efore 
Cim. 
9 
1 
6 
9 
7 
0 
6 
4 
0 
9 
Ί 
1 
8 
6 
1 
iti 
22 
8 
versus after 
cont. 
11 
¿t 
5 
6 
6 
0 
7 
7 
0 
11 
7 
0 
9 
7 
0 
¡Й 
31 
5 
duri ng 
Cim. 
9 
1 
6 
9 
6 
2 
6 
2 
2 
9 
3 
3 
8 
3 
1 
k] 
15 
14 
versus after 
cont. 
11 
Ц 
3 
6 
5 
0 
8 
5 
1 
11 
4 
0 
9 
3 
0 
45 
21 
4 
* Cim = Cimetidine treated patients; ** cont = controls; *** η = number of positive tests 
If there was an effect of Cimetidine on the immune response and a rebound 
phenomenon after stopping the drug, this would have become especially clear in 
comparing the results of tests during treatment to those after treatment, 
but no differences were demonstrated. 
In conclusion, in our study no effects of short-term treatment with 
Cimetidine on the immunological parameters studied in man were observed. 
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CHAPTER 10 
CIMETIDINE IN CLINICAL USE. A REVIEW 
Introduction 
The classical antihistamines do not antagonize the gastric acid stimulatory 
effect of histamine. Ash and Schild postulated the existence of 2 different 
receptors for histamine (1). The effects antagonized by the classical anti­
histamines were defined as mediated through H,-receptors and those who were 
not through hL-receptors (1). Black and his colleagues proved this hypothesis 
to be true by synthesizing compounds which were able to stimulate and antago­
nize hL-receptors selectively (2). Shortly afterwards H^-receptor antagonists 
for clinical use were developed: metiamide, later withdrawn because of bone 
marrow toxicity (3) and Cimetidine. At present the latter is the only commer-
cially available H^-receptor antagonist (Tagamet ). Pharmacological proper­
ties, results of animal studies and early clinical experiences with this drug 
have been reviewed (4). Since clinical experience with Cimetidine in the 
treatment of acid-peptic diseases has rapidly increased. 
The aim of this article is to review the various clinical indications for 
Cimetidine, both proven and under investigation, and its side-effects. 
Pharmacokinetics 
The bioavailability of Cimetidine after oral administration is about 70% 
(5). The blood concentration to achieve 50% inhibition of maximal gastric 
acid output (1С 50) is 0.5 - 1.0 yg/ml (6,7). Peak blood levels are reached 
60 - 90 minutes after oral administration and the mean peak blood concen­
tration after a 200 mg dose is 1.27 pg/ml (range 0.34 - 2.25 pg/ml). Blood 
levels remain above 0.5 pg/ml for more than 4 hours (6,8,9). Half-life is 
approximately 120 minutes. About 70% of an oral dose is excreted in the urine 
within 24 hours (6). However, one should bear in mind that there are great 
inter-individual differences in all these parameters (9,10) and that bioavai­
lability increases with age (11,12). 
Cimetidine is dosed three times 200 mg with meals and 400 mg at bedtime 
based on studies by Pounder and colleagues (13,14), achieving a reduction of 
mean 24 hour intragastric hydrogen ion concentration of 70%. Doubling of the 
day-time dose has no additional effect (13). Concomitant administration of 
anticholinergics enhances the effect of suboptimal doses of Cimetidine (15,16, 
17). Impaired renal function is the only condition known to require lowering 
of the dose (18.19). 
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Short term treatment 
üuod£na 1 _uj_c£r 
No drug has been so extensively studied in the treatment of duodenal ulcer 
as Cimetidine. These studies have contributed to a better insight in this 
disease. For instance no endoscopically controlled data on spontaneous hea-
ling and recurrence of duodenal ulcers were known, and the results of studies 
with Cimetidine urged to a re-evaluation of the utility of antacids in this 
disease (20,21). 
In multiple double blind controlled trials healing rate with Cimetidine 
after 4-6 weeks treatment was 57-84% as compared to 17-48% with a placebo 
(22-26). In all studies symptomatic relief in patients on Cimetidine was 
more pronounced than with a placebo. 
Gastric jjl£er 
The effect of Cimetidine in the treatment of gastric ulcer is less clear. 
Some studies reported the superiority of Cimetidine over a placebo in the 
healing of gastric ulcer, although without significant better symptomatic 
relief (27,28). But a number of studies fail to demonstrate a favourable 
effect (24,29,30). Presently it may be concluded that treatment with Cimeti-
dine is not better or worse than other medical therapies in gastric ulcer 
(31,32,33). 
Récurrent ^il£e£ 
At present 2 controlled studies demonstrate the efficacy of Cimetidine 
on healing and symptoms of recurrent ulcers after partial gastrectomy 
(34,35). A duration of therapy of 8 weeks is recommended for optimal results. 
Reflux_o£sopha£i_ti£ 
Incompetence of the lower oesophageal sphincter causes reflux of gastric 
juice into the oesophagus. Gastric acid does not always play the key role in 
reflux oesophagitis since reflux of pancreatic and biliary secretions is of 
additional varying importance. 
This complex aetiology is reflected in the equivocal results of the various 
clinical trials with Cimetidine in reflux oesophagitis. This is not amazing 
as Cimetidine is not known to affect other aetiological factors than gastric 
acid secretion. Lower oesophageal sphincter pressure is not influenced by 
Cimetidine (36,37). 
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Most studies showed a favourable effect of Cimetidine on heartburn symptoms 
(38-42), but in only some of these studies this was accompanied by a signifi-
cant healing of oesophagitis (39,42). In most studies a higher dose of 
Cimetidine was used: 4x400 mg daily during 8 weeks. 
^S_tr£S£"_e£Osjon_p£event2on 
The full aetiology of stress erosion formation in poly-traumatized, exten-
sively burned, post-operative or otherwise critically ill patients is unknown. 
Apart from other factors the presence of gastric acid is essential and dis-
ruption of the gastric mucosal barrier probably plays an important role (43, 
44). Cimetidine inhibits gastric acid secretion and raises the gastric poten-
tial difference (45). Nevertheless, Cimetidine does not affect the ionic 
permeability of the gastric mucosa (45) and it fails to prevent taurocholate 
induced disruption of the mucosal barrier (46,47). Yet, in experimental models, 
H2-receptor antagonists protect against stress induced gastric mucosal injury 
(48-51) and they also prevent aspirin induced mucosal damage in both man (52)and 
rats (53). In controlled trials Cimetidine prevented gastro-intestinal hae-
morrhage in patients with severe head injury (54), in patients with fulminant 
hepatic failure (55) and after renal transplantation (56). In patients with 
severe thermal injury Cimetidine was equally effective to an intensive antacid 
regimen (57), but in a recent study,in critically ill patients, antacids were 
superior (58). This ability of antacids to protect against stress ulcer bleeding 
was also earlier demonstrated (59,60).Further studies on this subject will 
have to elucidate whether and in which conditions Cimetidine is useful to 
prevent stress ulcer bleeding. 
Gas t r£-2rvt estin a 1 _ha епюг rha^e 
Controlled trials in patients with acute gastro-intestinal haemorrhage 
from peptic ulcer or erosions failed to demonstrate a more favourable effect 
of Cimetidine on bleeding or re-bleeding in comparison to a placebo (61-68). 
Pan crea t2C_i ji SJJ fΐ ici ency 
Oral pancreatic enzymes, as substitution therapy in patients with pancrea­
tic insufficiency, are inactivated by gastric acid and pepsin. Cimetidine 
administered before oral pancreatic extract increases intraduodenal activity 
of pancreatic enzymes (69) and enhances the effectiveness of this therapy 
(70). In contrast to conventional high dose bicarbonate therapy Cimetidine 
causes no discomfort. 
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Pancreatitis 
The rationale for the use of Cimetidine in acute pancreatitis is diminishing 
acidification of the duodenum in order to decrease the release of pancreas 
stimulating hormones. However, in experimental models in rats, Cimetidine was 
eventually found to induce pancreatitis (71) and to increase the mortality 
rate in pancreatitis (72). In a recent clinical controlled double blind study 
Cimetidine had neither a positive nor a negative effect on acute alcoholic 
pancreatitis (73). 
Zollinger-Ell is£n_syηdrome 
Hp-receptor antagonists have essentially changed the therapeutic approach 
of patients with the Zollinger-Ellison syndrome in whom radical tumor resection 
is impossible. Until recently the only possibility to control the symptoms of 
hypersecretion of gastric acid in many of these patients was total gastrectomy. 
Now there is ample proof that treatment with Cimetidine is effective in many 
cases making gastric operations unnecessary (74,75,76). Most patients respond 
well to the drug. Often they require higher doses or addition of an anticholi­
nergic drug (74). 
Long term treatment 
J)uodenal_u2œr 
Duodenal ulcer is a chronic disease with a high relapse tendency. This 
prompted to study the use of Cimetidine in the prevention of recurrent ulcers. 
There is abundant evidence that low dose Cimetidine is effective in preventing 
relapse of duodenal ulcers (77-83). The mean remission rate after 6 to 12 
months was 83% with Cimetidine treatment and 25% with a placebo. There was 
no difference in the results if 2x400 mg Cimetidine daily or only 400 mg at 
bedtime was used (84). Cimetidine does not cure duodenal ulcer disease. After 
cessation of treatment relapses in Cimetidine treated patients occur as fre-
quently as in patients on placebo (79,81,83,85). On the other hand in none of 
these studies the frequency of recurrence was increased after Cimetidine 
therapy. 
Gastri£ ^ісег 
The relapse rate in gastric ulcer is also high. Although the role of Cimeti­
dine in the healing of gastric ulcer is not established, 2 controlled trials 
studied the prevention of gastric ulcer relapse with Cimetidine and the 
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results obtained were comparable with those in duodenal ulcer (86,87). 
Recurrent u^£er 
One small open trial studied the effect of long term Cimetidine therapy 
in previously healed anastomotic ulceration. In this study 3 of 19 patients 
relapsed within one year treatment with 400 mg Cimetidine twice daily (34). 
Reflux_qes^)pha£it^_s 
Until now no data are available on long term treatment of reflux oesopha-
gitis with Cimetidine. 
Zo^lin^er-ElViscm syndrome_ 
Long term Cimetidine treatment proved to be very effective in controlling 
symptoms in Zollinger-Ellison patients. Many patients have been treated for 
much longer than one year with good result. In some instances dose adjustment 
was necessary but only in a few cases symptoms were uncontrolled (74,75,76). 
EfÏects i3n_s^rum_gastr2n_and_gastr2C_a£id. se£retion 
Studies on serum gastrin after long term treatment with Cimetidine show 
conflicting results. Some observers did not find any change at all (88). In 
other studies a rise of fasting serum gastrin level was seen while no change 
in meal stimulated gastrin occurred (89,90). Other investigators found an 
increase of meal stimulated gastrin only (91) and some observed a rise of 
both fasting and meal stimulated serum gastrin levels (92). However, since 
long term treatment with Cimetidine in man is not found to affect gastric 
acid secretion (77,88,89,90,93) a possible effect on serum gastrin is not 
likely to be of clinical importance. On the contrary, in rats,hyperplasia 
and hypertrophy of parietal cells occurred after long term H^-receptor 
antagonist administration, but in these studies extremely high doses were 
administered (94,95). 
Tolerance to Cimetidine does not develop during long term use: Cimetidine 
blood levels and inhibition of gastric acid secretion remain unchanged (8,77, 
90). 
Side effects 
ТохіаЛосіу_ 
In animal studies chronic as well as acute toxicity of Cimetidine was very 
low (96). In man no toxicity was observed after huge overdosage of Cimetidine. 
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In one case of self-poisoning 80 tablets of 200 mg were taken and blood Cime-
tidine level reached 113 pg/ml without any untoward effect (97). 
Genera]_ s.i^ e^ ejffects 
In general Cimetidine is very well tolerated. The occurrence of minor 
side-effects is limited and necessitates withdrawal of the drug in only few 
instances. Minor side-effects such as headache, tiredness, diarrhoea, skin 
rash and muscular pain, have been observed in nearly as much patients on 
Cimetidine as on placebo (98,99). 
J<i^ ne^ y 
A slight, often transient, rise in serum creatinine has been observed in 
many patients during Cimetidine treatment (98,99). This rise in serum creati-
nine, however, is not accompanied by a decrease of creatinine clearance. Mea-
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sûrement of Cr EDTA and inuline clearance did neither show a decrease of 
renal function. It is believed therefore that the rise in serum creatinine 
concentration is caused by a change of the tubular handling of creatinine by 
the kidney (100,101). 
In the United States 5 cases of interstitial nephritis, with a relapse in 
the single patient rechallenged,have been reported during Cimetidine treatment 
(Smith, Kline and French, personal communication). 
U^e_r 
Slight elevations of serum transaminase levels were as frequently seen in 
Cimetidine as in placebo treated patients. This rise is usually transitory and 
other biochemical liver function parameters are unaffected (98,99). Two pa-
tients on Cimetidine with a rise of serum transaminase levels of clinical con-
cern showed only "mild centrilobular necrosis" on liver biopsy (98). Recently 
a case of Cimetidine hepatitis, probably due to a hypersensitivity type of 
reaction, was reported (102). 
Haem ato 1 скрса 1 _ef fÇcjt s 
Unlike metiamide Cimetidine is not taken up by precursor cells in bone 
marrow. There are a few reports of Cimetidine influencing haematological 
parameters. Usually these patients had complicated histories and were treated 
with several other drugs. Probably these reactions were idiosyncratic. Pre-
sently, it can not be concluded that Cimetidine is bone-marrow toxic. This 
subject has recently been reviewed (103). 
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Endocrine effects 
Hall was the first to report gynaecomastia in patients during Cimetidine 
treatment (104) and consequently several other cases have been reported. 
In these patients no hormonal dysfunction was detected (104,105). Several 
studies report a rapid and brief stimulation of prolactin release after 
intravenous bolus injection of Cimetidine, but not after oral Cimetidine 
(106,107,108). In one study an influence on the hypothalamic-pituitary-
testicular axis was seen with a decrease of sperm counts.within normal limits, 
in 7 patients after 9 weeks Cimetidine therapy (109). In rats the existence 
of a certain anti-androgenic effect of Cimetidine is supported by several 
observations. The size of prostates and seminal vesicles decreased after 
one month high dose Cimetidine administration (96,110), and in in vitro 
experiments Cimetidine occupied androgen receptors (110,111). Most studies 
in man, however, did not disclose an effect on pituitary or testicular 
hormones after treatment with Cimetidine for up to 3 months (107, 112, 113). 
In controlled trials on short term and maintenance treatment with Cimetidine 
no sexual dysfunction was spontaneously reported by the patients. Such an 
effect however, may solely be detected after explicit inquiry. 
In conclusion, certain endocrine effects of Cimetidine are probably 
present but future studies will have to determine whether these effects are 
of clinical importance. Currently, attention and caution are recommended 
especially during long term treatment with Cimetidine. 
CNS-effects 
In several mostly older and severely ill patients with decreased renal 
and hepatic function cimetidine-induced mental confusion is reported (114, 
115). These symptoms subside rapidly after discontinuation of the drug. In 
these patients higher blood Cimetidine levels are reached and the blood-
brain barrier is permeable to Cimetidine (114). Adaptation of the dose under 
careful observation is recommended under these circumstances. 
_Inte£a£tj_ons_wi_th £the_r drugs^ 
Cimetidine enhances the effect of oral anticoagulants probably by inter-
fering with the metabolism of warfarin (116,117). Another study showed com-
parable interference with the metabolism of diazepam by Cimetidine (118). 
These interactions may be due to inhibition of the microsomal drug metabolism 
in the liver by Cimetidine as observed in the rat (119). For this reason 
Cimetidine might interact with the hepatic metabolism of other drugs and 
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therefore further studies in this field are indicated. 
^типо1_0£І£а_]_ efΐects 
A subpopulation of Τ lymphocytes is known to have hL-receptors (120) and 
therefore concern has arisen about a possible enhancement of delayed type 
hypersensitivity by Cimetidine which might cause an increase in renal allo­
graft rejection (121). Indeed, one study in man showed increased reaction to 
skin tests for delayed type hypersensitivity (122) and in another study an 
increased rejection of renal allografts was observed in dogs treated with 
Cimetidine (123). But the first study (122) had a disputable design (124) and 
we have not been able to reproduce its results (125). In a well defined trans­
plantation model of inbred mice Cimetidine did not increase skin graft rejec­
tion even if antigenic disparity was very weak (126). There are several other 
investigations which do not support a clinical important change in the immune 
response induced by Cimetidine (125,127,128). In one study in renal transplant 
recipients no increase of graft rejection was observed during Cimetidine 
therapy (129). 
Although there may be a certain inmunological effect of Cimetidine, up 
till now its clinical relevance is not established. 
£esponse_of malignant jjl£ers 
In patients with a malignant gastric ulcer Cimetidine may achieve a mis­
leading favourable response thus masking the diagnosis (130). 
Carc2n£g£nj_c_effects 
Concern has been raised because Cimetidine might form nitroso metabolites 
which might be involved in the pathogenesis of gastric cancer (131,132). Up 
till the time of writing there is no indication neither clinical nor experi­
mental that supports this hypothesis (133,134,135). 
Eff_ect_oji £a£dj_a£ Mstami_n£ re£e£tors 
Histamine hL-receptors have been demonstrated in the heart (136). There 
are a few case-reports in which arrythmias were attributed to Cimetidine 
treatment (137,138). In 2 studies on this subject, however, no effect of 
Cimetidine on heart rate could be established (139,140). 
Conclusion 
Cimetidine has proven to be a useful drug. It is clearly beneficial in 
the treatment of duodenal ulcer, recurrent ulcers after gastric surgery and 
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the Zollinger-Ellison syndrome. In view of uncertainty of long term side-
effects its use for maintenance treatment is recommended in selected patients 
only. Its role in the treatment of gastric ulcer and reflux oesophagitis is 
less clear. More data are required on stress ulcer prevention by Cimetidine. 
Side-effects are relatively rare and benign: presently the occurrence of 
endocrine effects and interactions with other drugs primarily cause anxiety, 
but full clinical inportance has not yet been established. Short term treat­
ment seems safe. 
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SAMENVATTING 
Hoofdstuk 1: Inleiding en opzet van het onderzoek 
Maagzuur speelt een grote rol bij de Pathogenese van het ulcus pepticum. 
De parietale cel in de maagwand produceert het maagzuur en wordt hiertoe aan-
gezet door acetylcholine, gastrine en histamine. Voor histamine zijn in de 
weefsels 2 verschillende receptoren aanwezig: de H,-receptoren via welke 
voornamelijk de contractie van glad spierweefsel in bronchi, ileum en arte-
riën wordt bewerkstelligd en de Hp-receptoren via welke als voornaamste effect 
de n.aagzuurproductie wordt gestimuleerd. 
Cimetidine is een stof die in staat is het effect van histamine op de H--
receptoren competitief te antagoneren. Zodoende wordt door Cimetidine de 
maagzuurproductie sterk geremd. Daarom wordt dit geneesmiddel toegepast bij 
die ziekten waarbij van de vermindering van het maagzuur een gunstig effect 
wordt verwacht. De onderzoeken die in het kader van deze studie met Cimetidine 
werden verricht worden in dit hoofdstuk beschreven. 
Hoofdstuk 2: De onderdrukking van de maagzuurproductie door middel van Cime-
tidine en de resultaten van een dubbelblind onderzoek naar de 
betekenis van Cimetidine voor de behandeling van peptische ulcera. 
Een daling van zowel de basale als de met pentagastrine gestimuleerde maag-
zuurproductie is vastgesteld na orale toediening van 200 mg Cimetidine aan 
14 patiënten met een ulcus duodeni en 8 met een ulcus ventriculi. 
In een dubbelblind onderzoek werd het effect van Cimetidine op de ulcus-
genezing vergeleken met dat van een placebo. Van 23 patiënten met een ulcus 
duodeni waren na 4 weken 10 van de 12 patiënten behandeld met Cimetidine en 
2 van de 11 patiënten behandeld met een placebo genezen (p<0,01). Bij de met 
Cimetidine behandelde patiënten waren ook de klachten significant verminderd. 
Bij 9 van de 13 patiënten met een ulcus ventriculi was het ulcus genezen 
na 4 weken behandeling met Cimetidine en bij 4 van de 11 die een placebobehan-
deling kregen (niet significant). Zowel bij de met Cimetidine als bij de met 
placebo behandelde patiënten verminderden de klachten significant. 
Als bijwerking werd bij enkele patiënten, zowel in de cimetidinegroep als 
in mindere mate ook in de placebogroep, een geringe voorbijgaande stijging 
gezien van het gehalte aan kreatinine en SGPT in het serum. 
Geconcludeerd wordt dat Cimetidine de maagzuurproductie effectief remt 
bij zowel ulcus duodeni als ulcus ventriculi patiënten. Patienten met een 
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ulcus duodeni reageren ook gunstig op de behandeling met Cimetidine. Bij pa-
tienten met een ulcus ventriculi is het nut van behandeling met Cimetidine 
minder duidelijk. 
Hoofdstuk 3: De behandeling van het anastomose ulcus na maagresectie met 
Cimetidine 
Eenentwintig patiënten met een anastomose ulcus na een maagresectie namen 
deel aan een dubbelblind onderzoek om het effect van Cimetidine op de ulcus-
genezing te vergelijken met dat van een placebo. Bij gastroscopie na 4 weken 
behandeling bleken 8 van de 12 met Cimetidine behandelde patiënten te zijn 
genezen en één van de 9 die een placebo kregen (p<0,05). De behandeling met 
Cimetidine had ook een gunstiger effect op de klachten van de patiënten dan 
placebobehandeling. Na ëén maand cimetidinebehandeling genas 67% van de pa-
tienten en na 2 maanden behandeling 86%. 
Gedurende 1 jaar onderhoudsbehandeling met 2x400 mg Cimetidine per dag 
kregen 3 van de 19 behandelde patiënten een recidief ulcus. 
Tijdens de behandeling werden geen bijwerkingen van betekenis geconstateerd. 
Geconcludeerd wordt dat het stoma ulcus na een maagresectie goed reageert 
op de behandeling met Cimetidine; in een aantal gevallen zal echter een lan-
gere behandelingsduur dan 4 weken nodig zijn. 
Hoofdstuk 4: De behandeling van ernstige ulcererende reflux oesofagitis met 
Cimetidine; de resultaten van een dubbelblind onderzoek gedu-
rende 8 weken en van een daaropvolgende onderhoudsbehandeling. 
Bij 20 patiënten met een door middel van oesofagoscopie aangetoonde ern-
stige ulcererende reflux oesofagitis werd in een dubbelblind onderzoek het 
effect van de behandeling met 1,6 g Cimetidine per dag vergeleken met dan van 
placebobehandeling. 
Na 8 weken was de oesofagitis bij 6 van de 13 met Cimetidine behandelde 
patiënten genezen en bij één van de 7 die met placebo werden behandeld (niet 
significant). Er was geen verschil tussen Cimetidine en placebo wat betreft 
het effect van de behandeling op de klachten. De klachtenvermindering bij de 
patiënten die genazen tijdens de cimetidinebehandeling was echter significant 
beter dan bij de patiënten die niet genazen met Cimetidine of bij de met pla-
cebo behandelde patiënten. De maagzuurproductie was niet verschillend bij de 
patiënten die wel en die niet genazen. Het genezingspercentage bereikt met 
Cimetidine werd niet hoger door de duur van de behandeling te verlengen. 
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Tijdens één jaar onderhoudsbehandeling met 2x400 mg Cimetidine per dag 
kregen 6 van de 7 genezen patiënten een recidief oesofagitis. 
Geconcludeerd wordt dat de behandeling van ernstige ulcererende reflux oe-
sofagitis met Cimetidine bij 50% van de patiënten succes had. Maar omdat deze 
ernstige vorm van oesofagitis de neiging heeft tot recidiveren ondanks onder-
houdsbehandeling met Cimetidine in een lagere dosering, zal deze behandeling 
over het algemeen alleen als voorbereiding op meer definitieve (chirurgische) 
therapie zinvol zijn. 
Hoofdstuk 5: De lange termijn behandeling van patiënten met het Zollinger-
Ellison syndroom met histamine Hg-receptor antagonisten. 
Drie patiënten met het Zollinger-Ellison syndroom werden gedurende 48, 
57 en 60 maanden met histamine Hg-receptor antagonisten behandeld. De behan-
deling bewerkstelligde een duidelijke vermindering van de maagzuurproductie en 
een effectieve verlichting van de klachten. Bij één van de patiënten moest de 
cimetidinedosering worden verdubbeld omdat na 15 maanden behandeling de basale 
maagzuurproductie toenam en opnieuw diarrhée optrad. De behandeling had geen 
invloed op de nuchtere of de door secretine gestimuleerde serum gastrinespie-
gels. Bij geen van de 3 patiënten werden tijdens de behandeling bijwerkingen 
geconstateerd. 
Hoofdstuk 6: Het effect van één jaar behandeling met Cimetidine op de maag-
zuurproductie, het serum gastrinegehalte en op het zuurremmende 
effect en de bloedspiegels van Cimetidine. 
Tweeentwintig patiënten met een genezen ulcus duodeni en 16 met een genezen 
ulcus ventriculi werden gedurende 1 jaar profylactisch met 2x400 mg Cimetidine 
per dag behandeld. De bepaling van de maagzuursecretie bij 20 ulcus duodeni en 
13 ulcus ventriculi patiënten liet geen verandering zien na 1 jaar behandeling. 
Bij 11 ulcus duodeni en '6 ulcus ventriculi patiënten werd het zuurremmend 
effect van Cimetidine bepaald en bij 9 ulcus duodeni en 4 ulcus ventriculi 
patiënten tevens de bloedspiegels van Cimetidine. Ook hierin traden geen 
veranderingen op na 1 jaar behandeling. Evenmin waren het nuchtere serum 
gastrinegehalte en de gastrine respons na een testmaaltijd vóór en na 1 jaar 
behandeling veranderd bij 7 ulcus duodeni en 6 ulcus ventriculi patiënten. 
Tijdens het jaar behandeling kregen 4 ulcus duodeni en 3 ulcus ventriculi 
patiënten een recidief ulcus. Bij controle gastroscopie na dit jaar werden 
geen asymptomatische ulcus recidieven gevonden bij de 18 ulcus duodeni en de 
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13 ulcus ventnculi patiënten die onderzocht werden. 
De conclusie is dat 1 jaar behandeling met Cimetidine geen invloed heeft 
op het serum gastrinegehalte, noch op de maagzuurproductie of het zuurremmend 
effect van Cimetidine bij patiënten met een ulcus duodeni of een ulcus ventri-
culi. 
Hoofdstuk 7: Is het bepalen van de bloedspiegels van Cimetidine klinisch van 
belang? 
Bloedspiegels van Cimetidine werden gedurende 5 uur na inname van 200 mg 
Cimetidine samen met een proefontbijt gemeten bij 13 ulcus duodeni, 5 ulcus 
ventnculi en 15 patiënten met een anastomose ulcus na een maagresectie. De 
gemiddelde piek bloedspiegel was 1,14+0,09 pg/ml (uiterste waarden: 0,54-1,94 
ug/ml ), de gemiddelde tijdsduur dat de bloedspiegel hoger was dan 0,5 pg/ml 
was 141+14 minuten (uiterste waarden:23-306 min) en de gemiddelde oppervlakte 
onder de Cimetidine bloedspiegelcurve was 166+12 yg.min.ml (uiterste waarden: 
96-280 yg.min.ml ). De variatiecoefficient van deze parameters was respec-
tievelijk 33%, 43% en 29%. Er waren geen significante verschillen tussen niet-
geopereerde patiënten en patiënten met een maagresectie wat betreft deze 
parameters. 
Bij patiënten bij wie de bloedspiegels tweemaal werden gemeten bleken deze 
zeer goed reproduceerbaar (correlatiecoefficient >0.90; p<0.001). 
Er was geen verschil in piek bloedspiegels, de tijdsduur dat de bloedspie-
gel hoger was dan 0,5 pg/ml en de oppervlakte onder de Cimetidine bloedspiegel-
curve tussen de patiënten, die na 4 weken behandeling met Cimetidine genazen 
en de patiënten die een langere behandelinqsduur nodig hadden. 
Bij de patiënten die een recidief ulcus kregen tijdens profylactische be-
handeling met Cimetidine waren de bloedspiegels ook niet lager dan bij de 
patiënten die geen recidief kregen, 
Geconcludeerd wordt dat er grote interindividuele verschillen in Cimeti-
dine bloedspiegels bestaan en dat deze verschillen reproduceerbaar zijn. Het 
bepalen van Cimetidine bloedspiegels lijkt echter klinisch niet van belang 
omdat de hoogte van deze spiegels geen aanwijzing geeft voor de klinische 
reactie van patiënten met een peptisch ulcus op de behandeling met Cimetidine. 
Hoofdstuk 8: Cimetidine veroorzaakt geen versnelde afstoting van huidtrans-
plantaten bij de muis. 
De invloed van Cimetidine op de overleving van huidstransplantaten bij de 
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muis werd bestudeerd in 4 allogene en één xeno^ene donor-ontvanger combinatie 
met toenemende histo-incompatibiliteit. Cimetidine, 25 mg/kg, werd om de 8 uur 
intraperitoneaal toegediend, terwijl controlegroepen met fysiologisch zout 
werden behandeld. Er was geen verschil in de transolantaatoverleving tussen 
de met Cimetidine behandelde muizen en de controlegroepen. 
Hoofdstuk 9: Behandeling met Cimetidine heeft geen invloed op immunologische 
parameters bij de mens. 
Bij 9 patiënten werden vóór, tijdens en 2 dagen na behandeling met 1,6 g 
Cimetidine per dag een aantal immunologische parameters onderzocht. In ver-
gelijking met 11 controlepersonen werd geen verschil gevonden in de reactie 
op huidtesten met 5 verschillende antigenen waaronder: candida albicans, bof, 
trichophyton, PPD en varidase. Het totaal aantal lymfocyten veranderde niet, 
evenmin als de reactie van lymfocyten in kweek op stimulatie met PHA, pokeweed 
en een cocktail van de antigenen zoals gebruikt voor de huidtesten. Ook de 
"mixed lymphocyte cultures" (KLC) en het stimulerend en responderend vermogen 
van de lymfocyten in de eenzijdige MLC veranderde niet.Het IgG, IgA en IgM 
gehalte bleef steeds onveranderd normaal. 
Hoofdstuk 10: De klinische toepassingsmogelijkheden van Cimetidine. 
Aan de hand van de literatuur wordt een overzicht gegeven van de verschil-
lende klinische toepassingsmogelijkheden van Cimetidine en de bijwerkingen die 
tot nu toe tijdens het gebruik van Cimetidine zijn geconstateerd. Geconclu-
deerd wordt dat behandeling met Cimetidine van het ulcus duodeni, het recidief 
ulcus na een maagresectie en het Zollinger-Ellison syndroom een duidelijk 
gunstig effect heeft. Vanwege de onzekerheid over bijwerkingen op langere ter-
mijn wordt langdurige behandeling alleen in speciale,daarvoor geselecteerde 
gevallen geadviseerd. Minder duidelijk is de rol van Cimetidine bij de behan-
deling van het ulcus ventriculi en reflux oesofagitis. Over het voorkómen 
van stress-ulcera door middel van Cimetidine zijn nog onvoldoende gegevens 
bekend. Tot nu toe zijn vrij weinig bijwerkingen tijdens het gebruik van Cime-
tidine geconstateerd en deze zijn relatief goedaardig. Op dit moment zijn de 
endocrinologische neveneffecten en de interactie met andere geneesmiddelen het 
meest van belang, hoewel de klinische consequenties hiervan nog niet volledig 
zijn vastgesteld. Kortdurende behandeling lijkt zonder risico's. 
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Cimetidine- en placebotabletten werden voor een deel door de firma Smith, 
Kline & French verstrekt. 
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De schrijver van dit proefschrift werd op 8 juli 1945 te Tilburg geboren. 
In 1964 behaalde hij het diploma gymnasium-ß aan het St. Willibrorduscollege 
te Zeist. Daarna studeerde hij qeneeskunde aan de Universiteit van Nijmegen 
en slaagde in 1973 voor het artsexamen. 
Hij begon de opleiding tot internist in februari 1974 in het St. Joseph 
Ziekenhuis te Eindhoven (Dr. FE van Dam, Dr. PFL Deckers, Dr. WMM Driessen 
en Dr. HAM de Rooy, internisten). 
Vanaf december 1975 werd deze opleiding voortgezet in de kliniek voor 
inwendige ziekten (hoofd: Prof.Dr. CLH f'ajoor) van het St. Radboudzieken-
huis te Nijmegen. 
Op 1 februari 1979 werd hij geregistreerd als internist. Momenteel is hij 
werkzaam op de algemene polikliniek van de universiteitskliniek voor 
inwendige ziekten (hoofd: Prof.Dr. A van 't Laar) van het St. Radboudzieken-
huis te Nijmegen. 
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STELLINGEN 
1 Voor de medicamenteuze behandeling van het ulcus duodeni is Cimetidine 
een goede keus. 
2 De behandeling van patiënten met het Zollinger-Ellison syndroom met een 
Hg-receptor antagonist maakt in de meeste gevallen maagoperaties onnodig. 
3 Bloedspiegels van Cimetidine geven geen indruk over het effekt van de 
behandeling met dit geneesmiddel. 
4 De indicatie tot chirurgische therapie van het ulcus duodeni is door de 
introductie van Cimetidine niet essentieel gewijzigd. 
5 Profylactische behandeling met Cimetidine van patiënten na een niertrans-
plantatie biedt een effectieve bescherming tegen gastro-intestinale bloe-
dingen terwijl deze therapie de transplantaatoverleving niet beïnvloedt. 
VAN ROERMUND HPC, persoonlijke mededeling 
6 Evenals de huisarts dient ook de specialist zich er van bewust te zijn 
dat hoe meer onderzoek bij een patient wordt verricht des te sterker deze 
er van overtuigd kan raken aan een somatische aandoening te lijden. 
Nascholingscursus voor Hulsartsen "Huisarts en Somatische Fixatie", 
PAOG Nijmegen, I98O 
7 Bij zuigelingen met aanhoudende diarree dient een anatomische oorzaak 
hiervoor te worden uitgesloten. 
FESTEN C: Total colonic aganglionosis, a diagnostic problem. Ζ. Kinder-
chir. 27: 330, 1979 
8 Ondanks het opzienbarende effekt op het gehoor van het plaatsen van trom­
melvliesbuisjes, levert dit toch geen wezenlijke bijdrage tot de genezing 
van het glue-ear. 
LILDHOLDT T: Unilateral grommet insertion and adenoidectomy in bilate­
ral secretory otitis media: preliminary report of the results in 91 
children. Clin Otolaryngology 't: 87, I979 
9 Verwijzing door de arts van zijn patient kan zeer wel, zij het onbewust, 
tot doel hebben de spanning in de relatie tussen arts en patient te ver-
minderen. 
10 Om tot reproduceerbare resultaten te kunnen komen bij het vergelijken van 
inhalatie-provokatietesten, is het noodzakelijk dat niet alleen de mate 
van bronchoconstrictie bij de aanvang van het onderzoek maar ook de mate 
van aspecifieke hyperreactiviteit van de bronchiaalboom vergelijkbaar zijn. 
KILLIAN 0, COCKCROFT DW, HARGRb'AVE FE e.a.: Factors in a llergen- induced 
astma: relevance of the intensity of the airways allergic reaction and 
non-specific bronchial reactivity. Clin Allergy 6: 219, 1976 
11 Het optreden van een paradoxale groeihormoonstijging tijdens de orale glu-
cosetolerantietest is in de puberteit een fysiologisch verschijnsel zonder 
pathologische betekenis. 
PIETERS GFFM, SMALS AGH, KLOPPENBORG PWC: J Clin Endocrinol Metab (in 
press) 
12 Als motief voor het in dienst nemen van specialisten in ziekenhuizen wor-
den vaak hoofdzakelijk financiële argumenten aangehaald. Het laten func-
tioneren van specialisten in dienstverband is echter voornamelijk gewenst 
om redenen van kwaliteit van de gezondheidszorg en van organisatie en 
beheer van de ziekenhuizen. 
Henk Festen 
20 juni 1980 


